Bioorganic & Medicinal Chemistry 19 (2011) 1751-1770



Contents lists available at ScienceDirect

Bioorganic & Medicinal Chemistry



journal homepage: www.elsevier.com/locate/bmc

17,20-Lyase inhibitors. Part 4: Design, synthesis and structure–activity relationships of naphthylmethylimidazole derivatives as novel 17,20-lyase inhibitors

Tomohiro Kaku^{a,*}, Nobuyuki Matsunaga^a, Akio Ojida^e, Toshimasa Tanaka^b, Takahito Hara^c, Masuo Yamaoka^c, Masami Kusaka^c, Akihiro Tasaka^d

^a Medicinal Chemistry Research Laboratories, Takeda Pharmaceutical Company, Ltd, 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka 532-8686, Japan

^b Discovery Research Center, Takeda Pharmaceutical Company, Ltd, 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka 532-8686, Japan

^c Pharmacology Research Laboratories, Takeda Pharmaceutical Company, Ltd, 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka 532-8686, Japan

^d Environment and Safety Department, Takeda Pharmaceutical Company, Ltd, 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka 532-8686, Japan

e Graduate School of Pharmaceutical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka 812-8582, Japan

ARTICLE INFO

Article history: Received 27 November 2010 Revised 7 January 2011 Accepted 11 January 2011 Available online 15 January 2011

Keywords: 17,20-Lyase 11-Hydroxylase Testosterone Prostate cancer

ABSTRACT

A novel series of naphthylmethylimidazole derivatives and related compounds have been investigated as selective 17,20-lyase inhibitors. Optimization of the substituent at the 6-position on the naphthalene ring was performed to yield a methylcarbamoyl derivative, which exhibited potent inhibitory activity against human 17,20-lyase and promising selectivity (>200-fold) for 17,20-lyase over CYP3A4. Further modifications of the methylcarbamoyl derivative led to the discovery of the corresponding tricyclic compound, which showed highly potent activity against human 17,20-lyase (IC₅₀ 19 nM) and good selectivity (>1000-fold) for inhibition of 17,20-lyase over CYP3A4. Additional biological evaluation revealed that the tricyclic compound had potent in vivo efficacy in monkeys and favorable pharmacokinetic profiles when administered in rats. Asymmetric synthesis of the selective tricyclic inhibitor was also achieved using a chiral α -hydroxy ketone.

© 2011 Elsevier Ltd. All rights reserved.

1. Introduction

Prostate cancer is one of the most prevalent cancers among men in the USA and Europe.¹ In most cases, growth, maintenance and progression of prostate cancer is androgen-dependent.^{2,3} Therefore, the current first-line treatment for prostate cancer is hormone therapy, such as surgical castration or medical castration via administration of a luteinizing hormone-releasing hormone (LH-RH) agonist, which reduces the production of testosterone secreted by the testes. However, resistance to this therapy eventually occurs and this clinical condition is referred to as castration-resistant prostate cancer (CRPC).⁴ Despite very many studies in this field, the mechanism of progression to CRPC has not been fully understood. However, recent studies have suggested that residual adrenal androgen dehydroepiandrosterone (DHEA) after surgical castration could be responsible for the development of CRPC.^{5,6}

Thus one possible target for CRPC treatment is the enzyme 17,20-lyase, which plays a crucial role in androgen biosynthesis. This is because inhibition of 17,20-lyase would be expected to

decrease serum and rogen levels secreted not only by the testes but also by the adrenal glands. $^{7-9}$

In recent years, several groups have reported the development of steroidal and non-steroidal inhibitors of 17,20-lyase,^{10–44} such as YM-116²⁷ and abiraterone acetate,¹¹ which have been evaluated in clinical studies, and we have also disclosed the design of 17,20-lyase inhibitors such as compounds **1a**⁴⁵ and **1b** (Kaku et al., manuscript in preparation), as shown in Figure 1.

We have previously reported that the introduction of a small alkoxy group such as methoxy or ethoxy group at the 6-position of the naphthalene ring of these compounds slightly increased 17,20-lyase inhibition. Moreover, docking studies of **1a** using a homology model for human 17,20-lyase suggested that the methoxy group at the 6-position on the naphthalene ring might form a hydrogen bond with threonine 101 (Thr101) in the active site of the enzyme. Unfortunately, compound **1a** was found to also be a potent inhibitor of CYP3A4, with an IC₅₀ value of less than 1000 nM, as shown in Table 1. Therefore, we continued further modification of this series of compounds, aiming to improve the selectivity for 17,20-lyase over CYP3A4. In this report, we discuss the synthesis and structure–activity relationships (SAR) of novel naphthylmethylimidazole derivatives and related compounds as 17,20-lyase inhibitors. Additionally, asymmetric synthesis of the

^{*} Corresponding author. Tel.: +81 6 6300 6546; fax: +81 6 6300 6306. *E-mail address:* Kaku_Tomohiro@takeda.co.jp (T. Kaku).

^{0968-0896/\$ -} see front matter \odot 2011 Elsevier Ltd. All rights reserved. doi:10.1016/j.bmc.2011.01.017



Figure 1. Chemical structures of previously developed 17,20-lyase inhibitors.

Table 1

Effect of R substituent on inhibition of rat and human 17,20-lyase and human CYP3A4



Compound No.	R	Enzyme inhibition IC ₅₀ (nl			Ratio ^a
		17,20-Lyase		CYP3A4	
		Rat	Human		
1a	OMe	21	28	<1000	<36
6	Ac	14	28	1400	50
10a	NHAc	29	39	<1000	<26
10b	NHCONHMe	11	36	<1000	<28
22	COOMe	43	24	1400	58
24b	CONHMe	6	16	3600	225

 a Ratio is given by IC_{50} value of CYP3A4 inhibition/IC_{50} value of human 17,20-lyase inhibition.

selected compound using the chiral α -hydroxy ketone was achieved and is described in detail.

2. Chemistry

The synthesis of ketone **6** is outlined in Scheme 1. As reported previously,⁴⁶ conversion of 6-bromo-2-naphthol to dibromide **2** was achieved by treatment with triphenylphosphine (PPh₃) and bromine at 70–300 °C. Treating dibromide **2** with a sub-stoichiometric amount of *n*-butyllithium (*n*-BuLi) in tetrahydrofuran (THF) followed by the addition of ketone **3**, gave bromide **4** in high yield. Sequential treatment of bromide **4** with *n*-BuLi generated the lithium dianion, to which Weinreb's amide was added at -78 °C to give a moderate yield of ketone **5**. Finally, removal of the trityl group with pyridine hydrochloride in methanol (MeOH) provided the targeted ketone **6**.

The syntheses of **10a** and **10b** are shown in Scheme 2. Conversion of bromide **4** into **7** was performed by Buchwald's method using tris(dibenzylideneactone)dipalladium (Pd₂(dba)₂), 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (BINAP), sodium *tert*-butoxide (*tert*-BuONa) and benzophenonimine, to provide good yields of **7**. The resulting imine **7** was deprotected to give **8**, which was then treated with acetic anhydride or phenyl chloroformate, followed by methylamine hydrochloride to yield **9a** and **9b**, respectively. Subsequent deprotections of **9a** and **9b** were performed by treatment with pyridine hydrochloride to give **10a** and **10b**, respectively.

The syntheses of the trisubstituted naphthalene derivatives **11b–d** are shown in Scheme 3. 6-Bromo-2-naphthol was chlorinated at the 1-position with sulfuryl chloride to give a moderate yield of **11b**. After Wolff–Kishner reduction of 1-formyl-2-naphthol, **12** was treated with bromine to give 6-brominated **11c** in high yield. Trimethoxyborane-catalyzed reduction of **13** with lithium borohydride gave alcohol **14**. The alcohol **14** was successively oxidized with manganese dioxide (MnO₂) to produce **15** in high yield (in two steps). After Wolff–Kishner reduction of the aldehyde **15**, conversion of the methoxy group of **16** with BBr₃ was carried out to give a high yield of phenol **11d**.

The syntheses of **22** and **24a–24h** are shown in Scheme 4. Phenols **11a–d** were protected with *tert*-butyldimethylsilyl chloride (TBSCl), the resulting silyl ethers were treated with *n*-BuLi at -78 °C, followed by addition of ketone **3** to produce excellent yields of **18a–d**, respectively. Removal of the *tert*-butyldimethylsilyl (TBS) group with tetrabutylammonium fluoride (TBAF) provided phenols **19a–d**, which were allowed to react with trifluoromethansulfonic anhydride (Tf₂O) to give **20a–d**, respectively. Methoxycarbonylation of **20a–d** using palladium(II) acetate (Pd(OAc)₂) and 1,1'-bis(diphenylphosphino)ferrocene (dppf) in MeOH and *N*,*N*-dimethylformamide (DMF) under CO atmosphere gave the corresponding esters, which underwent hydrolysis, followed by treatment with diphenylphosphoryl azide (DPPA) and ammonium bicarbonate or 1-ethyl-3-(3-dimethylaminopropyl)



Scheme 1. Reagents and conditions: (a) (1) PPh₃, Br₂, CH₃CN, 70 °C, then 300 °C, 29%; (b) (1) *n*-BuLi, THF, -50 °C; (2) **3**, THF, -50 °C, 93%; (c) (1) *n*-BuLi, THF, -70 °C; (2) *N*-methoxy-*N*-methylacetamide, THF, -70 °C, 54%; (d) pyridine hydrochloride, MeOH, CHCl₃, 60 °C, 81%.



Scheme 2. Reagents and conditions: (a) benzophenoneimine, Pd₂(dba)₂, BINAP, *tert*-BuONa, toluene, 80 °C, 87%; (b) NH₂OH-HCl, AcONa, THF, MeOH, rt; (c) Ac₂O, pyridine, rt; (d) (1) phenyl chloroformate, pyridine, THF, 0 °C, then (2) MeNH₂·HCl, 10 N NaOH, DMSO, rt; (e) pyridine hydrochloride, MeOH, CHCl₃, 60 °C, 31–80% in three steps.



Scheme 3. Reagents and conditions: (a) SO₂Cl₂, Et₂O, 0 °C to rt, 51%; (b) hydrazine monohydrate, KOH, triethyleneglycol, 170–190 °C, 89%; (c) Br₂, AcOH, 10–20 °C, 99%; (d) LiBH₄, cat.B(OMe)₃, THF; refluxed; (e) MnO₂, CH₂Cl₂, refluxed, 94% in two steps; (f) hydrazine monohydrate, KOH, triethyleneglycol, 160–180 °C, 98%; (g) BBr₃, CH₂Cl₂, -70 °C to rt, 89%.

carbodiimide hydrochloride (EDCI-HCl) and alkylamine to provide carbamoyl derivatives **23a–h** in good yield. Deprotections of **21a** and **23a–h** were performed according to a similar method as described for **6** to give the desired compounds **22** and **24a–h**, respectively.

The syntheses of **27a** and **27b** are shown in Scheme 5. Substituted naphthalene **21c** was brominated using *N*-bromosuccinimide (NBS) and 2,2'-azobis(2-methylpropionitrile) (AIBN) to yield **25**, which was subjected to lactam cyclization to form **26a** and **26b**, respectively. Deprotections of each compound yielded the desired **27a** and **27b**. The regioisomers **30a** and **30b** were also synthesized from **21d** in a similar manner, as shown in Scheme 6.

To examine the stereochemical requirement at the chiral centers of these inhibitors, optical resolutions of **27a** and **27b** into (–)-**27a** and (+)-**27a**, and (–)-**27b** and (+)-**27b**, respectively, were performed using preparative HPLC with a Chiralpak AD column. Additionally, as shown in Scheme 7, (+)-**27b** was converted to the 4-bromobenzenesulfonyl derivative **31** and the absolute configuration of (+)-**27b** was confirmed to be *R* by X-ray crystallographic analysis of **31**, as shown in Figure 2.

2.1. Asymmetric synthesis of compound (-)-27b

The asymmetric synthesis of (–)-**27b** is shown in Scheme 8. Diastereoselective Grignard reactions are versatile and effective methods for providing chiral tertiary alcohols.^{47–49} Our group has previously reported the application of this method to substrates with an α -hydroxy ketone and established effective methods to synthesize chiral hydroxymethylimidazole derivatives utilizing diastereoselective Grignard reactions.^{50,51} To construct the chiral center of (–)-**27b**, we used our previously reported method using α -hydroxy ketone **34b**. The key intermediate **34b** was easily prepared from the known morpholine amide **33**.⁵² The synthesized **33** was treated with lithium species generated from **32b** and *n*-BuLi to give **34a**, which was followed by deprotection of the TBS group with TBAF to afford moderate yield of the desired **34b**.

Treatment of **34b** with isopropylmagnesium bromide gave the crude (1*S*,2*R*)-diol **35** in a diastereoselective manner together with some by-products, followed by crystallization to give (1*S*,2*R*)-diol **35** with 95% purity; this was used without further purification in the next step. *ortho* lithiation of **35** followed by the addition of



Scheme 4. Reagents and conditions: (a) TBSCl, imidazole, DMF, 0 °C to rt, 85–98%; (b) (1) *n*-BuLi, THF, –70 °C; (2) **3**, 84–93%; (c) TBAF, THF, 0 °C to rt, 89–98%; (d) Tf₂O, pyridine, 0 °C, 61–94%; (e) CO, Pd(OAC)₂, dppf, Et₃N, DMF, MeOH, 70 °C, 81–95%; (f) pyridine hydrochloride, MeOH, CHCl₃, 60 °C, 94%; (g) (1) 4 N NaOH, THF, MeOH, 60 °C, then (2) for **23a**, NH₄HCO₃, DPPA, Et₃N, DMF, rt, quant., for **23b–h**, R³NH₂, EDCI-HCl, HOBt·H₂O, Et₃N, DMF, rt, 75% to quant.; (h) pyridine hydrochloride, MeOH, CHCl₃, 60 °C, 73–93%.



Scheme 5. Reagents and conditions: (a) NBS, AIBN, CCl₄, refluxed, 59% as a mixture of 25 and 21c (25:21c = ca. 7:1); (b) for 26a, saturated NH₃ in MeOH, THF, 0 °C to rt, 26%; (c) for 26b, 40% NH₂Me in MeOH, rt, quant.; (d) pyridine hydrochloride, MeOH, CHCl₃, 60 °C, 75–90%.

DMF gave a mixture of **36a** and **36b** (**36a**:**36b** = ca. 6:1), which was then treated with methylamine under reductive amination conditions to yield a mixture of **37a** and **37b**. Subsequent internal cyclization of a mixture of **37a** and **37b** using lithium diisopropylamide (LDA), followed by recrystallization gave a mixture of the regioisomers such as **38a** and **38b** (**38a**:**38b** = 93:7) in moderate yield. Swern oxidation of a mixture of **38a** and **38b**, and subsequent recrystallization of the product gave **39** with >99% purity, which was then subjected to the α -bromination condition using pyridinium bromide perbromide to give α -bromoketone **40**.

Since the direct conversion from **40** to (–)-**27b** gave insufficient yield of (–)-**27b** with 2% (not shown in Scheme 8), imidazole ring closure was performed after protection of **40** with a trimethylsilyl group by *N*,*O*-bis(trimethylsilyl)acetamide. The obtained **41** was



Scheme 6. Reagents and conditions: (a) NBS, AIBN, CCl₄, refluxed, quant.; (b) for **29a**, saturated NH₃ in MeOH, THF, 0 °C to rt; (c) for **29b**, 40% NH₂Me in MeOH, rt; (d) pyridine hydrochloride, MeOH, CHCl₃, 60 °C, 22–64% in two steps.



Scheme 7. Reagents and conditions: (a) optical resolution using preparative HPLC on a Chiralpak AD column; (b) 4-bromobenzenesulfonyl chloride, Et₃N, DMF, rt, 88%.



Figure 2. ORTEP drawing of 31.

then subjected to the reaction conditions using formamidine acetate in saturated NH_3 solution, shown in Scheme 8 to give (–)-**27b** in moderate chemical yield with excellent ee (>99%ee). In summary, an 11-step method was developed for asymmetric synthesis of the selected (–)-**27b** from 6-bromo-2-naphthoic acid **32a** using the diastereoselective Grignard reaction as a key step to construct the chiral center of (–)-**27b**.

3. Results and discussion

3.1. SARs for 17,20-lyase, CYP3A4, and 11-hydroxylase

All compounds synthesized as racemates were tested in vitro for inhibition of rat 17,20-lyase, human 17,20-lyase and CYP3A4. Selected compounds were resolved by HPLC and the resultant



Scheme 8. Reagents and conditions: (a) (1) SOCl₂, DMF, THF, 60 °C; (2) diisopropylamine, Et₃N, THF, 0 °C-rt; 88%; (b) (1) *n*-BuLi, toluene, THF, -70 °C; (c) **33**, THF, -78 °C; (c) TBAF, THF, -10 to 0 °C, 58% from **33**; (d) isopropylmagnesium bromide, THF, -10 to 0 °C, 54%; (e) *n*-BuLi, TMEDA, DMF, THF, -70 °C; (f) 2 M MeNH₂ in THF, NaBH(OAc)₃, AcOH, CH₂Cl₂, rt; (g) LDA, THF, -70 to -10 °C, 42% as a mixture of **38a** and **38b**; (h) DMSO, (COCl)₂, Et₃N, CH₂Cl₂, -70 to -20 °C, 33%; (i) pyridinium bromide perbromide, THF, 0 °C to rt; (j) *N*,O-bis(trimethylsilyl)acetamide, cat. TBAF, DMF, rt, 54% from **39**; (k) formamidine acetate, saturated NH₃ in MeOH, THF, -15 °C to rt, 54%, >99% ee.

optical isomers were further examined in vitro for inhibition of rat 11-hydroxylase, which is responsible for the biosynthesis of gluco-corticoid and mineralocorticoid.

As previously described,⁴⁵ we have shown that the substituents at the 6-position of the naphthalene ring are likely to have an important role in hydrogen bond formation with Thr101 in the enzyme. Therefore, a number of modifications to optimize the substituent at the 6-position of the naphthalene ring were investigated.

The results of a SAR study on replacement of the substituent at the 6-position of the naphthalene ring are shown in Table 1. On the basis of a docking study of 1a, hydrogen bond acceptors were examined as replacements for the methoxy group of compound **1a.** Although replacing the methoxy group (**1a**) with an acetyl group (6) or a methoxycarbonyl group (22) had little effect on potency against human 17,20-lyase with slightly improved selectivity between human 17,20-lyase and CYP3A4, replacing the methoxy group (1a) with an acetamide group (10a) or a methylureido group (10b) led to slightly decreased inhibitory activity against human 17,20-lyase without improved selectivity between human 17,20lyase and CYP3A4. Replacement of the methoxy group (1a) with a methylcarbamoyl group (24b), on the other hand, resulted in both increased inhibitory activity against human 17,20-lyase and a promising improvement in selectivity between the two enzymes. These results indicate that the methylcarbamoyl group on the naphthalene ring is optimal in terms of both inhibition of 17,20-lyase and selectivity between 17,20-lyase and CYP3A4.

We then focused on modification of the methylcarbamoyl group and the introduction of a substituent at the 5- or 7-position of the naphthalene ring. The results are shown in Table 2. Replacement of

Table 2

Effect of R¹, R², R³ substituents on inhibition of rat and human 17,20-lyase and human CYP3A4



Compound No.	\mathbb{R}^1	R ²	R ³	Enzyme inhibition IC ₅₀ (nM)		
				17,20-Lyase		CYP3A4
				Rat	Human	
24a	Н	Н	Н	<10	30	3700
24b	Н	Н	Me	6	16	3600
24c	Н	Н	Et	11	46	5700
24d	Н	Н	Pr	13	38	3400
24e	Н	Н	iPr	12	75	9300
24f	Cl	Н	Me	91	200	>10000
24g	Me	Н	Me	200	160	>10000
24h	Н	Me	Me	12	39	3600

the methylcarbamoyl group (**24b**) with a carbamoyl (**24a**) or other small alkyl carbamoyl group (**24c**, **24d** and **24e**) resulted in a 2–5fold loss in potency against human 17,20-lyase and a 2–3-fold decrease in selectivity for human 17,20-lyase over CYP3A4. The introduction of a substituent at the 5-position of the naphthalene ring also resulted in decreased potency. For example, incorporation of a chlorine substitution (**24f**) at the 5-position resulted in a decrease in potency of more than an order of magnitude when compared with the unsubstituted **24b**. Even a relatively small methyl group (24g) led to marked reductions in potency against human 17.20-lyase. On the other hand, introduction of a methyl group at the 7-position of the naphthalene ring (24h) resulted in only a slight decrease in inhibition of human 17,20-lyase and no change in inhibition of CYP3A4 compared with 24b. These results suggested that the methylcarbamoyl group (24b) was optimum in size and the bulkiness at the 5- or 7-position may have some effect on fixing the conformation of the carbamoyl group.

Therefore, fixing the angle of the carbamoyl group seemed to be a promising strategy for further development, and tricyclic compounds such as 27a, 27b, 30a and 30b were prepared to make the conformation of the carbonyl group more rigid. As a result, all of these tricvclic compounds had reduced inhibitory activity against CYP3A4 compared with 24b, but maintained activity against 17.20-lvase, shown in Table 3. Among them, **27b** had the best selectivity for 17.20-lvase over CYP3A4 by more than 400fold.

Further investigations regarding the stereochemical requirement at the chiral center of these inhibitors were performed using optical isomers such as (-)-27a, (+)-27a, (-)-27b, and (+)-27b, respectively, as shown in Table 4. As expected, each isomer exhibited markedly different potencies against 17,20-lyase, as well as selectivity between 17,20-lyase and CYP3A4. Each (-)-isomer had potent inhibitory activity against 17,20-lyase and selectivity by more than 500-fold for 17,20-lyase over CYP3A4. These data indicate that the orientation of the isopropyl group at the benzyl moiety may be critical for binding to targeted 17,20-lyase.

Table 3

Effect of R¹ substituent on inhibition of rat and human 17,20-lyase and human CYP3A4



Table 4

Stereochemical requirement for inhibitory activities of (±)-27a and (±)-27b against rat and human 17,20-lyase, rat 11-hydroxylase and human CYP3A4 enzymes



Compound No.	\mathbb{R}^1		Enzyme inhibition IC ₅₀ (nM)			
		17,2	0-Lyase	11-Hydroxylase	CYP3A4	
		Rat	Human			
(-)- 27a	Н	<10	15	13	>10000	
(+)- 27a	Н	180	60	220	7400	
(−) -27b	Me	<10	19	>1000	>10000	
(+)- 27b	Me	110	270	>1000	>10000	

Table 5

Inhibitory effect of (-)-27b on marker enzyme activities in microsomes expressing human CYP isoforms

Compound No.		Enzyme inhibition IC ₅₀ (nM)					
	17,20-Lyase			Human CYP isoforms			
	Rat	Human	CYP2C8	CYP2C9	CYP2D6	CYP3A4	
(-)- 27b	<10	19	28000	<3000	>30000	27000	



Figure 3. Docking of (-)-27b in the 17,20-lyase homology model.

Compounds (-)-27a, (+)-27a, (-)-27b, and (+)-27b were also tested for their ability to inhibit rat 11-hydroxylase. Compounds (-)-27a and (+)-27a showed highly potent inhibitory activity against 11-hydroxylase, while (-)-27b and (+)-27b showed low levels of 11-hydroxylase inhibition at concentrations of up to 1000 nM.

3.2. Enzyme selectivity

During a series of in vitro studies, (-)-27b was further investigated against other P450 enzymes such as CYP2D6, CYP2C8, and CYP2C9, which have been identified as important P450 enzymes involved in drug metabolism.^{53–56} As shown in Table 5, (–)-27b demonstrated specific inhibition of CYP2C9 versus CYP2C8, CYP2D6, and CYP3A4; however, it also showed good selectivity (>1000-fold) for inhibition of human 17,20-lyase over CYP2C8, CYP2D6 and CYP3A4.

Table 6

In vivo effects of (-)-27b on serum testosterone and DHEA levels after single oral dosing (1 mg/kg) in monkeys

Compound	% of average 0 h values, mean ± SD				
	Serum testosterone		Serum DHEA		
	4 h	8 h	4 h	8 h	
Vehicle (–) -27b (1 mg/kg)	89.1 ± 15.6 13.2 ± 7.5 ^b	68.5 ± 27.3 9.8 ± 4.9^{a}	105.7 ± 4.2 16.8 ± 7.0 ^c	38.5 ± 18.4 7.7 ± 4.3 ^a	

n = 3.

^a P <0.05 versus vehicle (Dunnett test).

^b P <0.005 versus vehicle (Dunnett test).

 Table 7

 Selected pharmacokinetic data for compound (-)-27b after oral or intravenous (IV) administration in rats

Dosage route	Dose (mg/kg)	$T_{\max}(h)$	C _{max} (µg/mL)	AUC^{a} (µg h/mL)	Bioavailability (%)
Oral IV	10 1	0.42 ± 0.14	2.943 ± 0.611	7.315 ± 2.148 0.573 ± 0.030	127.7 ± 38.1

Mean \pm SD (*n* = 3). ^a 0-24 h.

3.3. Docking experiments

The docking of (–)-27b was studied using a homology model of 17,20-lyase. In the docking experiment it was postulated that (–)-27b should be connected to the catalytic heme iron via the nitrogen of the imidazole ring moiety, and the proposed binding mode of (–)-27b is shown in Figure 3. Results of docking studies indicated that the tricyclic ring of (–)-27b occupied a hydrophobic region in the active site of the enzyme and the carbonyl moiety on the lactam ring formed a hydrogen bond with Thr101. These findings are consistent with our previous results on the docking study of 1a.⁴⁵ Furthermore, an additional hydrogen bond between the hydroxyl group at the linker position between the tricyclic and imidazole rings of (–)-27b with Thr306 was also observed in this model.

3.4. In vivo efficacy

Based on the in vitro profiles, (-)-**27b** was selected for further biological investigation. In a monkey model both testicular androgen testosterone and adrenal androgen DHEA levels were examined to evaluate in vivo potency of (-)-**27b**. As shown in Table 6, (-)-**27b** markedly reduced serum testosterone and DHEA levels at 4 and 8 h after administration of an oral dose (1 mg/kg) in monkeys. These results indicate that compound (-)-**27b** could be useful for the treatment of both hormone-dependent and castration-resistant prostate cancer.

3.5. Pharmacokinetics

Pharmacokinetic studies of (–)-27b were performed in rats (not evaluated in monkeys). As shown in Table 7, (–)-27b demonstrated good pharmacokinetic profiles with large oral AUC and excellent bioavailability values; these results are encouraging for the further development of (–)-27b as a therapeutic agent.

4. Conclusions

We have successfully synthesized a new class of potent and selective 17,20-lyase inhibitors. Replacement of the substituent at the 6-position of the naphthalene ring showed that a methylcarbamoyl group was optimal in terms of potency and selectivity. Further modifications aimed at fixing the orientation of the carbonyl group of the inhibitor yielded tricyclic compounds **27a** and **27b** that were potent and selective human 17,20-lyase inhibitors. Among them (–)-**27b** showed good selectivity (>1000-fold) for the inhibition of 17,20-lyase over CYP3A4, while showing potent inhibitory activity against 17,20-lyase. Additional biological evaluation revealed that (–)-**27b** exhibited potent in vivo efficacy at an oral dose of 1 mg/kg in monkeys and showed favorable pharmacokinetic profiles when administered to rats. Further evaluation on this series is ongoing, with the aim of identifying a new potent and highly selective 17,20-lyase inhibitor.

5. Experimental

Melting points were determined using a BUCHI Melting Point B-545 apparatus and are uncorrected. Infrared (IR) spectra were taken using a SHIMADZU FT-IR-8200PC spectrometer. ¹H NMR spectra were recorded using a Varian Gemini-200, Varian Mercury-300 spectrometer, or a Bruker AVANCE-300 spectrometer. ¹³C NMR spectra were recorded using a Bruker AVANCE-300 spectrometer; chemical shifts are given in ppm with tetramethylsilane as an internal standard, and coupling constants (1) are measured in hertz (Hz). The following abbreviations are used: s = singlet, d = doublet, t = triplet, m = multiplet, br s = broad singlet. LCMS was performed on the Agilent1200Sl and Agilent6130MS apparatus with 5 mM aqueous AcONH₄ solution/ acetonitrile mobile phase. Reactions were followed by TLC on Silica Gel 60 F₂₅₄ precoated TLC plates (Merck, Darmstadt, Germany). Column chromatography was performed using Silica Gel 60 (E. Merck, Darmstadt, Germany). Compounds 3 (Kaku, T. et al., manuscript in preparation) and 13^{57} were prepared in the same manner as described previously.

5.1. 2,6-Dibromonaphthalene (2)

Bromine (78.8 g, 493 mmol) was added dropwise to a cooled (0 °C) solution of triphenylphosphine (129 g, 493 mmol) in anhydrous CH₃CN (200 mL) and the solution was stirred for 30 min at rt. A solution of 6-bromo-2-naphthol (100 g, 448 mmol) in anhydrous acetonitrile (CH₃CN) (200 mL) was added, and the reaction mixture was stirred for a further 2 h at 70 °C. After removal of the solvent (bath temp was increased to 140 °C), the residue was heated to 300 °C for 1 h. After being cooled to 100 °C, the black tar was dissolved in toluene (100 mL), and cooled to rt while stirring. The resulting solution was washed with 1 N NaOH and water, followed by drying over MgSO₄. The solvent was removed in vacuo and the residue was dissolved in MeOH (50 mL). The precipitate was filtered and washed with MeOH (200 mL) and diisopropylether (iPr_2O), successively, to give **2** (37.2 g, 29%) as a grey powder. The analytical sample was obtained by recrystallization from AcOEt (light brown plates). ¹H NMR (CDCl₃) δ : 7.51–7.62 (4H, m), 7.94 (2H, s). IR (KBr): 1568, 1481, 1175, 1134, 1065, 885, 853. 816 cm⁻¹. Anal. Calcd for C₁₀H₆Br₂: C, 42.00; H, 2.11. Found: C, 42.28; H, 2.18.

5.2. 1-(6-Bromo-2-naphthyl)-2-methyl-1-(1-trityl-1*H*-imidazol-4-yl)-1-propanol (4)

n-BuLi (1.6 M; 59.0 mL, 94.4 mmol) was added dropwise to a cooled (-50 °C) solution of **2** (27.0 g, 94.4 mmol) in anhydrous THF (1300 mL) , and the solution was stirred for 20 min at -50 °C. A solution of **3** (23.9 g, 62.9 mmol) in anhydrous THF (200 mL) was added dropwise over 20 min, and the reaction mixture was stirred for 20 min at -50 °C. After dilution with water, the organic phase was separated. The aqueous phase was extracted with AcOEt. The extracts were washed with brine and dried over MgSO₄, and then concentrated in vacuo. The residue was washed with hot AcOEt to give **4** (34.4 g, 93%) as a light brown powder. The analytical sample was obtained by recrystallization from THF–hexane (colorless powder). ¹H NMR (CDCl₃) δ : 0.72 (3H, d, J = 6.7 Hz), 0.95 (3H, d, J = 6.7 Hz), 2.45–2.58 (1H, m), 3.75 (1H, s), 6.80 (1H, d, J = 1.8, 8.7 Hz), 7.57 (1H, dd, J = 1.8, 8.8 Hz),

7.63–7.69 (2H, m), 7.94 (1H, d, J = 1.8 Hz), 8.02 (1H, s). IR (KBr): 3241, 2967, 1493, 1445, 1169, 1017, 826, 812, 756, 747, 700 cm ⁻¹. Anal. Calcd for C₃₆H₃₁N₂OBr: C, 73.59; H, 5.32; N, 4.77. Found: C, 73.89; H, 5.11; N, 4.63.

5.3. 1-{6-[1-Hydroxy-2-methyl-1-(1-trityl-1*H*-imidazol-4-yl)-propyl]-2-naphthyl}-1-ethanone (5)

n-BuLi (1.6 M; 16.4 mL, 26.2 mmol) was added dropwise to a cooled (-70 °C) solution of **4** (7.0 g, 11.9 mmol) in anhydrous THF (150 mL) , and the solution was stirred for 20 min at -70 °C. A solution of *N*-methoxy-*N*-methylacetamide (2.45 g, 23.8 mmol) in anhydrous THF (10 mL) was added, and the reaction mixture was stirred for 20 min at -70 °C. After dilution with water, the resulting mixture was extracted with AcOEt ($\times 2$). The combined organic layers were washed with brine, dried over MgSO₄, and concentrated in vacuo. The residue was purified by column chromatography on silica gel (hexane/THF = 6:1-3:1) to give 5 (3.53 g, 54%) as a colorless powder. The analytical sample was obtained by recrystallization from *i*-Pr₂O (colorless powder). ¹H NMR $(CDCl_3) \delta$: 0.74 (3H, d, I = 6.8 Hz), 0.97 (3H, d, I = 6.8 Hz), 2.48– 2.61 (1H, m), 2.72 (3H, s), 3.75 (1H, br s), 6.83 (1H, d, J = 1.4 Hz), 7.10-7.17 (6H, m), 7.30-7.37 (10H, m), 7.65 (1H, dd, J=1.6, 8.8 Hz), 7.84 (1H, d, J = 8.8 Hz), 7.87 (1H, d, J = 8.8 Hz), 8.01 (1H, dd, J = 1.6, 8.8 Hz), 8.07 (1H, s), 8.42 (1H, s). IR (KBr): 3519, 2963, 1671, 1275, 1231, 1140, 747, 700 cm⁻¹. Anal. Calcd for C₃₈-H₃₄N₂O₂: C, 82.88; H, 6.22; N, 5.09. Found: C, 82.96; H, 6.17; N, 5.37.

5.4. 1-{6-[1-Hydroxy-1-(1*H*-imidazol-4-yl)-2-methylpropyl]-2-naphthyl}-1-ethanone (6)

A mixture of 5 (350 mg, 0.64 mmol) and pyridine hydrochloride (148 mg, 1.28 mmol) in MeOH (4 mL) and CHCl₃ (2 mL) was stirred at 60 °C for 3 h. The mixture was diluted with aq NaHCO₃ solution and the resulting mixture was extracted with AcOEt. The combined organic lavers were washed with brine, dried over MgSO₄. After removing the solvent, the residue was purified by column chromatography on silica gel $(CH_2Cl_2/MeOH = 20:1-10:1)$ to give 6 (159 mg, 81%) as a colorless powder. The analytical sample was obtained by recrystallization from AcOEt as a colorless powder. Mp 180.0–182.0 °C. ¹H NMR (CDCl₃ + CD₃OD) δ : 0.81 (3H, d, *J* = 6.7 Hz), 1.02 (3H, d, *J* = 6.7 Hz), 2.73–2.86 (4H, m), 7.05 (1H, d, *I* = 1.1 Hz), 7.56 (1H, d, *I* = 1.1 Hz), 7.73 (1H, dd, *I* = 1.7, 8.7 Hz), 7.89 (1H, d, J = 8.7 Hz), 7.92 (1H, d, J = 8.7 Hz), 7.99 (1H, dd, J = 1.7, 8.7 Hz), 8.11 (1H, s), 8.46 (1H, s). IR (KBr): 3235, 2969, 1672, 1306, 1289, 1044, 895, 824, 789 cm⁻¹. LCMS (API): m/z309.2 [M+H]⁺. Anal. Calcd for C₁₉H₂₀N₂O₂·0.1AcOEt: C, 73.46; H, 6.61; N, 8.83. Found: C, 73.29; H, 6.57; N, 8.84.

5.5. 1-[6-[(Diphenylmethylene)amino]-2-naphthyl]-2-methyl-1-(1-trityl-1*H*-imidazol-4-yl)-1-propanol (7)

A mixture of **4** (14.0 g, 23.8 mmol), benzophenoneimine (5.18 g, 28.6 mmol), *tert*-BuONa (5.72 g, 59.5 mmol), $Pd_2(dba)_3$ (440 mg, 0.48 mmol), and *R*-(+)-BINAP (872 mg, 1.40 mmol) in anhydrous toluene (140 mL) was heated at 80 °C for 18 h under Ar atmosphere. After dilution with AcOEt, the resulting mixture was passed through Celite. The filtrate was concentrated in vacuo, and the residue was purified by column chromatography on silica gel (hexane/THF = 1:1) and recrystallized from AcOEt–hexane (×2) to give **7** (14.3 g, 87%) as a yellow powder. ¹H NMR (CDCl₃) δ : 0.74 (3H, d, *J* = 6.7 Hz), 0.93 (3H, d, *J* = 6.7 Hz), 2.42–2.56 (1H, d), 3.65 (1H, br s), 6.79 (1H, d, *J* = 1.4 Hz), 6.87 (1H, dd, *J* = 2.0, 8.6 Hz), 7.10–7.57 (28H, m), 7.76 (1H, d, *J* = 2.0 Hz), 7.80 (1H, d, *J* = 1.4 Hz), 7.86 (1H, s). IR (KBr): 3453, 2969, 1493, 1445, 1256,

1163, 1005, 812, 748 cm⁻¹. Anal. Calcd for $C_{49}H_{41}N_3O$ ·0.3THF: C, 84.98; H, 6.17; N, 5.92. Found: C, 84.87; H, 6.27; N, 5.74.

5.6. 1-(6-Amino-2-naphthyl)-2-methyl-1-(1-trityl-1*H*-imidazol-4-yl)-1-propanol (8)

Sodium acetate (4.02 g, 49.0 mmol) and hydroxylamine hydrochloride (2.52 g, 36.3 mmol) were added to a solution of 7 (14.0 g, 20.4 mmol) in anhydrous THF (100 mL) and MeOH (100 mL) and the mixture was stirred for 40 min at rt. After concentration in vacuo, the residue was diluted with 0.2 N NaOH, and the resulting mixture was extracted with AcOEt (\times 2). The combined organic layers were washed with brine and dried over MgSO₄ followed by concentration in vacuo to give 8 (orange-colored oil), which was used in the next reaction without further purification. The analytical sample was obtained by recrystallization from AcOEt (pale vellow powder). ¹H NMR (CDCl₃) δ : 0.75 (3H. d. *J* = 6.8 Hz), 0.93 (3H, d, *J* = 6.8 Hz), 2.44–2.57 (1H, m), 3.62 (1H, br s), 6.79 (1H, d, / = 1.4 Hz), 6.89–6.94 (2H, m), 7.11–7.18 (6H, m), 7.29–7.36 (10H, m), 7.44 (1H, dd, J = 1.8, 8.8 Hz), 7.50 (1H, d, *J* = 8.8 Hz), 7.61 (1H, d, *J* = 8.4 Hz), 7.86 (1H, d, *J* = 1.2 Hz). IR (KBr): 3370, 3092, 2963, 1634, 1485, 1445, 760, 747, 700 cm⁻¹. Anal. Calcd for C₃₆H₃₃N₃O·0.2AcOEt: C, 81.66; H, 6.44; N, 7.76. Found: C, 81.55; H, 6.51; N, 7.66.

5.7. N-{6-[1-Hydroxy-2-methyl-1-(1-trityl-1*H*-imidazol-4-yl)propyl]-2-naphthyl}acetamide (9a)

Pyridine (5.0 mL, 61.2 mmol) and acetic anhydride (3.9 mL, 40.8 mmol) were added to a crude mixture of **8** in anhydrous CH₂Cl₂ (100 mL) and stirred for 40 min at rt. After dilution with saturated NaHCO₃ (200 mL), the mixture was extracted with CH₂Cl₂ (×3). The combined organic layers were dried over MgSO₄ and concentrated in vacuo. The residue was recrystallized from AcOEt to give **9a** (10.9 g, 95% from **7**) as a pale yellow powder. ¹H NMR (CDCl₃ + CD₃OD) δ : 0.75 (3H, d, *J* = 6.7 Hz), 0.95 (3H, d, *J* = 6.7 Hz), 2.20 (3H, s), 2.57–2.71 (1H, m), 6.87 (1H, d, *J* = 1.4 Hz), 7.10–7.15 (6H, m), 7.32–7.54 (12H, m), 7.68–7.77 (2H, m), 7.92 (1H, s), 8.15 (1H, s), 9.60 (1H, br s). IR (KBr): 3058, 2969, 1686, 1493, 1298, 1011, 747, 700 cm⁻¹. Anal. Calcd for C₃₈H₃₅-N₃O₂·0.3AcOEt: C, 79.51; H, 6.37; N, 7.10. Found: C, 79.50; H, 6.47; N, 7.28.

5.8. *N*-{6-[1-Hydroxy-1-(1*H*-imidazol-4-yl)-2-methylpropyl]-2naphthyl}acetamide (10a)

Compound **10a** was prepared in the same manner as described for the preparation of **6**. Yield 84%, colorless powder. Mp 186.0– 188.0 °C. ¹H NMR (CDCl₃ + CD₃OD) δ : 0.79 (3H, d, *J* = 6.8 Hz), 1.0 (3H, d, *J* = 6.8 Hz), 2.17 (3H, s), 2.63–2.76 (1H, m), 6.99 (1H, s), 7.43–7.54 (3H, m), 7.65–7.74 (2H, m), 7.91 (1H, s), 8.11 (1H, s). IR (KBr): 3248, 2971, 1669, 1557, 1495, 1391, 1296, 818 cm⁻¹. LCMS (API): *m/z* 324.2 [M+H]⁺. Anal. Calcd for C₁₉H₂₁N₃O₂: C, 70.57; H, 6.55; N, 12.99. Found: C, 70.58; H, 6.90; N, 12.94.

5.9. N'-{6-[1-Hydroxy-1-(1*H*-imidazol-4-yl)-2-methylpropyl]-2-naphthyl}-N-methylurea (10b)

Phenyl chloroformate (0.50 mL, 4.01 mmol) was added dropwise to a cooled (0 °C) solution of **8** (1.40 g, 2.67 mmol) and pyridine (0.65 mL, 8.01 mmol) in anhydrous THF (10 mL) and stirred for 30 min at 0 °C. After pouring into phosphate buffer (pH 7.0), the resulting mixture was extracted with AcOEt (×2). The combined organic layers were washed with brine and dried over MgSO₄, followed by concentrating in vacuo to give the carbamate (red viscous oil) which was used for the next reaction without further purification. Methylamine hydrochloride (360 mg, 5.34 mmol) and 10 N NaOH (0.54 mL, 5.4 mmol) were added to a stirred solution of the carbamate in DMSO (5 mL), and the reaction mixture was stirred for 1 h at rt. After dilution with 0.5 N NaOH, the resulting mixture was extracted with AcOEt (\times 2). The combined organic layers were washed with brine and dried over MgSO₄ followed by concentrating in vacuo. The residue was purified by column chromatography on silica gel (hexane/AcOEt = 1:2-1:4) to give **9b** (984 mg) as a pale yellow powder, which contained a small amount of impurities. **9b** (850 mg) was used as a starting material. Using the same procedure as described for the synthesis of 6, 10b (278 mg, 31% from 8) was obtained as colorless amorphous solid. ¹H NMR (CDCl₃ + CD₃OD) δ : 0.79 (3H, d, J = 6.9 Hz), 0.97 (3H, d, J = 6.9 Hz), 2.74–2.87 (1H, m), 2.79 (3H, s), 7.03 (1H, s), 7.38 (1H, dd, / = 2.2, 8.8 Hz), 7.55–7.66 (3H, m), 7.72 (1H, d, *J* = 9.0 Hz), 7.87 (1H, d, *J* = 2.0 Hz), 7.94 (1H, s). IR (KBr): 3320, 2971, 1655, 1555, 1493, 1248 cm⁻¹. LCMS (API): *m/z* 339.2 [M+H]⁺. Anal. Calcd for C₁₉H₂₂N₄O₂·H₂O: C, 64.03; H, 6.79; N, 15.72. Found: C, 64.06; H, 6.72; N, 15.63.

5.10. 6-Bromo-1-chloro-2-naphthol (11b)

Sulfuryl chloride (6.48 mL, 80.7 mmol) was added dropwise to a cooled (0 °C) solution of 6-bromo-2-naphthol (15.0 g, 67.2 mmol) in anhydrous Et₂O (80 mL) and stirred for 1 h at rt. After removal of the solvent in vacuo, the residue was diluted with AcOEt. The solution was washed with water and brine, and then dried over MgSO₄. After concentration in vacuo, the residue was recrystallized from *i*-Pr₂O-hexane (×2) to give **11b** (8.89 g, 51%) as a light brown powder. ¹H NMR (CDCl₃) δ : 5.90 (1H, s), 7.27 (1H, d, *J* = 9.0 Hz), 7.61 (1H, d, *J* = 9.0 Hz), 7.63 (1H, dd, *J* = 2.2, 9.0 Hz), 7.92 (1H, d, *J* = 9.0 Hz), 7.94 (1H, d, *J* = 2.2 Hz). IR (KBr): 3491, 3432, 1589, 1200, 1184, 939, 806 cm⁻¹. Anal. Calcd for C₁₀H₆OBrCl: C, 46.64; H, 2.35. Found: C, 46.44; H, 2.35.

5.11. 1-Methyl-2-naphthol (12)

A mixture of 2-hydroxy-1-naphthaldehyde (20.0 g, 116 mmol), hydrazine monohydrate (16.9 mL, 348 mmol) and KOH (20 g) in triethyleneglycol (150 mL) was slowly heated to 170 °C in a round-bottomed flask equipped with Dean-Stark apparatus. The mixture was then heated at 170 °C for 90 min and at 190 °C for a further 20 min. After cooling to rt, the mixture was poured into water and acidified with concentrated HCl. The precipitate was filtered, washed with water, and dried in vacuo to give **12** (16.3 g, 89%) as a pale yellow powder. The analytical sample was obtained by recrystallization from *i*-Pr₂O-hexane (colorless needles). ¹H NMR (CDCl₃) δ : 2.52 (3H, s), 4.91 (1H, br s), 7.04 (1H, d, J = 8.8 Hz), 7.29–7.37 (1H, m), 7.44–7.52 (1H, m), 7.60 (1H, d, J = 8.8 Hz), 7.75 (1H, d, J = 8.0 Hz), 7.90 (1H, d, J = 8.4 Hz). IR (KBr): 3295, 1514, 1354, 1227, 1213, 806, 742 cm⁻¹. Anal. Calcd for C₁₁H₁₀O: C, 83.51; H, 6.37. Found: C, 83.55; H, 6.46.

5.12. 6-Bromo-1-methyl-2-naphthol (11c)

A solution of bromine (16.1 g, 101 mL) in AcOH (30 mL) was added dropwise to a cooled (10 °C) solution of **12** (16.0 g, 101 mmol) in AcOH (50 mL); the temperature of the solution was maintained at 10–20 °C. After stirring for 15 min at 15–20 °C, the mixture was poured into water. The precipitate was filtered, washed with water, and dried in vacuo to give **11c** (23.7 g, 99%) as a reddish powder. ¹H NMR (CDCl₃) δ : 2.49 (3H, s), 4.94 (1H, s), 7.05 (1H, d, *J* = 8.8 Hz), 7.50 (1H, d, *J* = 8.8 Hz), 7.52 (1H, dd, *J* = 2.2, 9.0 Hz), 7.76 (1H, d *J* = 9.0 Hz), 7.89 (1H, d, *J* = 2.2 Hz). IR (KBr): 3245, 1591, 1497, 1356, 1341, 1198, 1080, 893, 878,

810 cm⁻¹. Anal. Calcd for $C_{11}H_9OBr$: C, 55.72; H, 3.83. Found: C, 55.70; H, 3.81.

5.13. (7-Bromo-3-methoxy-2-naphthyl)methanol (14)

Trimethoxyborane (1.60 mL, 13.6 mmol) was added dropwise to a solution of lithium borohydride (2.96 g, 136 mmol) and 13^{56} (40.0 g, 136 mmol) in anhydrous THF (150 mL), and the solution was refluxed for 90 min. After cooling to 0 °C, water was carefully added, and the mixture was acidified with 6 N HCl followed by extraction with AcOEt (×2). The combined organic layers were washed with 1 N NaOH (×2) and brine, and then dried over MgSO₄. The solvent was removed in vacuo to give **14** as a colorless powder, which was used for the next reaction without further purification. The analytical sample was obtained by recrystallization from AcOEt–hexane (colorless needles). ¹H NMR (CDCl₃) δ : 3.97 (3H, s), 4.82 (2H, s), 7.09 (1H, s), 7.49 (1H, dd, *J* = 1.8, 8.8 Hz), 7.60 (1H, d, *J* = 8.8 Hz), 7.65 (1H, s), 7.91 (1H, d, *J* = 1.8 Hz). IR (KBr): 3239, 1497, 1248, 1215, 1065, 1049, 839 cm⁻¹. Anal. Calcd for C₁₂H₁₁O₂Br: C, 53.96; H, 4.15. Found: C, 53.76; H, 3.93.

5.14. 7-Bromo-3-methoxy-2-naphthaldehyde (15)

A suspension of **14** and MnO₂ (200 g) in CH₂Cl₂ (600 mL) was refluxed for 1 h. The mixture was filtered through Celite, and the filtrate was concentrated in vacuo to give **15** (33.9 g, 94% from **13**) as a yellow powder. The analytical sample was obtained by recrystallization from AcOEt-hexane (colorless plates). ¹H NMR (CDCl₃) δ : 4.01 (3H, s), 7.13 (1H, s), 7.58 (2H, s), 7.98 (1H, s), 8.20 (1H, s), 10.55 (1H, s). IR (KBr): 2882, 1680, 1620, 1250, 1157 cm ⁻¹. Anal. Calcd for C₁₂H₉O₂Br: C, 54.37; H, 3.42. Found: C, 54.41; H, 3.46.

5.15. 6-Bromo-2-methoxy-3-methylnaphthalene (16)

A mixture of **15** (13.0 g, 49.0 mmol), hydrazine monohydrate (7.13 mL, 147 mmol) and KOH (13.0 g) in triethyleneglycol (100 mL) was slowly heated to 160 °C in a round-bottomed flask equipped with Dean-Stark apparatus. Evolution of N₂ gas started at 100 °C. The mixture was heated at 160 °C for 20 min and then at 180 °C for a further 10 min. After cooling to rt, the mixture was poured into water. The precipitate was washed with water and dried in vacuo to give **16** (12.1 g, 98%) as pale yellow plates. The analytical sample was obtained by recrystallization from AcOEt–hexane (colorless plates). ¹H NMR (CDCl₃) δ : 2.35 (3H, s), 3.91 (3H, s), 7.01 (1H, s), 7.40–7.45 (2H, m), 7.56 (1H, d, *J* = 8.4 Hz), 7.82 (1H, s). IR (KBr): 2978, 1590, 1490, 1256, 1157, 1119, 1019, 903, 851 cm⁻¹. Anal. Calcd for C₁₂H₁₁OBr: C, 57.39; H, 4.42. Found: C, 57.27; H, 4.47.

5.16. 6-Bromo-3-methyl-2-naphthol (11d)

BBr₃ (1 M solution in CH₂Cl₂; 55.0 mL) was added dropwise to a cooled (-70 °C) solution of **16** (11.5 g, 45.8 mmol) in anhydrous CH₂Cl₂ (120 mL), and the mixture was slowly heated to rt. After stirring for 2 h at rt, the reaction was quenched with water at 0 °C. The resulting mixture was extracted with CH₂Cl₂ (×2). The combined organic layers were washed with brine, dried over MgSO₄, and then concentrated in vacuo. The residue was purified by column chromatography on silica gel (hexane/AcOEt = 2:1) and washed with hexane to give **11d** (9.67 g, 89%) as a pale yellow powder. The analytical sample was obtained by recrystallization from AcOEt–hexane (pale yellow prisms). ¹H NMR (CDCl₃) δ : 2.40 (3H, s), 5.12 (1H, s), 7.02 (1H, s), 7.40 (1H, dd, *J* = 1.8, 8.8 Hz), 7.46–7.50 (2H, m), 7.82 (1H, s). IR (KBr): 3562, 1589, 1512, 1232,

1186, 1153, 1103, 920, 905, 860 $\rm cm^{-1}.$ Anal. Calcd for $C_{11}\rm H_9OBr:$ C, 55.72; H, 3.83. Found: C, 55.65; H, 3.63.

5.17. 2-Bromo-6-(tert-butyldimethylsilyloxy)naphthalene (17a)

TBSCl (37.0 g, 246 mmol) was added to a cooled (0 °C) solution of 6-bromo-2-naphthol (50.0 g, 224 mmol) and imidazole (22.9 g, 336 mmol) in DMF (200 mL), and the solution was stirred for 2 h at rt. After dilution with water, the resulting mixture was extracted with AcOEt (×2). The combined organic layers were washed with water and brine, and then dried over MgSO₄. After removal of the solvent in vacuo, the residue was recrystallized from MeOH (20 mL) to give **17a** (71.3 g, 94%) as colorless plates. ¹H NMR (CDCl₃) δ : 0.24 (6H, s), 1.01 (9H, s), 7.08 (1H, dd, *J* = 2.4, 8.8 Hz), 7.15 (1H, d, *J* = 2.4 Hz), 7.46 (1H, dd, *J* = 1.8, 8.8 Hz), 7.54 (1H, d, *J* = 8.8 Hz), 7.61 (1H, d, *J* = 8.8 Hz), 7.90 (1H, d, *J* = 1.8 Hz). IR (KBr): 2957, 2930, 2857, 1256, 874, 797, 783 cm⁻¹. Anal. Calcd for C₁₆H₂₁OBrSi: C, 56.97; H, 6.27; Br, 23.69. Found: C, 56.94; H, 6.26. Compounds **17b–d** were prepared using the same method as described for the preparation of **17a**.

5.18. 6-Bromo-2-[(*tert*-butyldimethylsilyl)oxy]-1-chloronaph-thalene (17b)

Yield 98%, pale yellow oil. ¹H NMR (CDCl₃) δ : 0.27 (6H, s), 1.07 (9H, s), 7.14 (1H, d, *J* = 8.8 Hz), 7.56 (1H, d, *J* = 8.8 Hz), 7.60 (1H, dd, *J* = 2.0, 9.0 Hz), 7.93 (1H, d, *J* = 2.0 Hz), 8.07 (1H, d, *J* = 9.0 Hz). IR (KBr): 2930, 1588, 1487, 1352, 1271, 1246, 960, 839 cm⁻¹.

5.19. 6-Bromo-2-[(*tert*-butyldimethylsilyl)oxy]-1-methylnaph-thalene (17c)

Yield 85%, pale yellow plates. ¹H NMR (CDCl₃) δ : 0.23 (6H, s), 1.05 (9H, s), 2.49 (3H, s), 7.07 (1H, d, *J* = 8.8 Hz), 7.48 (1H, d, *J* = 8.8 Hz), 7.51 (1H, dd, *J* = 2.2, 9.2 Hz), 7.77 (1H, d, *J* = 9.2 Hz), 7.89 (1H, d, *J* = 2.2 Hz). IR (KBr): 2926, 1460, 1258, 928, 841, 781 cm⁻¹. Anal. Calcd for C₁₇H₂₃OBrSi: C, 58.11; H, 6.60; Br, 22.74. Found: C, 57.97; H, 6.56.

5.20. 6-Bromo-2-[(*tert*-butyldimethylsilyl)oxy]-3-methylnaph-thalene (17d)

Yield 98%, pale yellow powder. ¹H NMR (CDCl₃) δ : 0.28 (6H, s), 1.04 (9H, s), 2.35 (3H, s), 7.05 (1H, s), 7.40 (1H, dd, *J* = 2.0, 8.6 Hz), 7.48–7.52 (2H, m), 7.81 (1H, d, *J* = 1.8 Hz). IR (KBr): 2928, 2856, 1587, 1460, 1254, 840, 781 cm⁻¹. Anal. Calcd for C₁₇H₂₃OBrSi: C, 58.11; H, 6.60; Br, 22.74. Found: C, 58.23; H, 6.64.

5.21. 1-(6-*tert*-Butyldimethylsilyloxy-2-naphthyl)-2-methyl-1-(1-trityl-1*H*-imidazol-4-yl)-1-propanol (18a)

n-BuLi (1.6 M; 55.6 mL, 88.9 mmol) was added dropwise to a cooled (-70 °C) solution of **17a** (30.0 g, 88.9 mmol) in anhydrous THF (300 mL), and the solution was stirred for 20 min at -70 °C. A solution of **3** (22.6 g, 59.3 mmol) in anhydrous THF (150 mL) was added dropwise over 30 min, and the reaction mixture was stirred for 20 min at -70 °C. After dilution with water, the organic phase was separated and the aqueous phase was extracted with AcOEt. The extracts were washed with brine and dried over MgSO₄. After removal of the solvent in vacuo, the residue was purified by column chromatography on silica gel (hexane/AcOEt = 1:1) and recrystallized from iPr_2O -hexane to give **18a** (34.8 g, 92%) as a colorless powder. ¹H NMR (CDCl₃) δ : 0.23 (6H, s), 0.75 (3H, d, J = 6.8 Hz), 0.95 (3H, d, J = 6.6 Hz), 1.02 (9H, s), 2.45–2.59 (1H, m), 3.66 (1H, s), 6.80 (1H, d, J = 1.4 Hz), 7.04 (1H, dd, J = 2.4, 8.8 Hz), 7.11–7.16 (6H, m), 7.30–7.34 (11H, m), 7.49 (1H, dd, J = 1.6,

8.6 Hz), 7.60 (1H, d, J = 8.6 Hz), 7.68 (1H, d, J = 8.8 Hz), 7.94 (1H, s). IR (KBr): 3158, 2955, 2930, 1601, 1480, 1260, 843, 700 cm⁻¹. Anal. Calcd for C₄₂H₄₆N₂O₂Si: C, 78.95; H, 7.26; N, 4.38. Found: C, 79.05; H, 7.26; N, 4.47. Compounds **18b–d** were prepared using the same method as described for the preparation of **18a**.

5.22. 1-(6-{[*tert*-Butyl(dimethyl)silyl]oxy}-5-chloro-2-naphthyl)-2-methyl-1-(1-trityl-1*H*-imidazol-4-yl)propan-1-ol (18b)

Yield 84%, colorless powder. ¹H NMR (CDCl₃) δ : 0.25 (6H, s), 0.74 (3H, d, *J* = 6.8 Hz), 0.95 (3H, d, *J* = 6.6 Hz), 1.07 (9H, s), 2.45–2.59 (1H, m), 3.70 (1H, s), 6.80 (1H, d, *J* = 1.2 Hz), 7.07–7.16 (7H, m), 7.29–7.34 (10H, m), 7.59 (1H, dd, *J* = 1.8, 8.8 Hz), 7.61 (1H, d, *J* = 8.8 Hz), 7.99 (1H, d, *J* = 1.8 Hz), 8.07 (1H, d, *J* = 8.8 Hz). IR (KBr): 3155, 2957, 1599, 1474, 1360, 1252, 1020, 964, 841, 700 cm⁻¹.

5.23. 1-(6-{[*tert*-Butyl(dimethyl)silyl]oxy}-5-methyl-2-naphthyl)-2-methyl-1-(1-trityl-1*H*-imidazol-4-yl)propan-1-ol (18c)

Yield 89%, colorless powder. ¹H NMR (CDCl₃) δ : 0.22 (6H, s), 0.75 (3H, d, *J* = 6.6 Hz), 0.95 (3H, d, *J* = 6.6 Hz), 1.05 (9H, s), 2.44–2.60 (4H, m), 3.64 (1H, s), 6.80 (1H, d, *J* = 1.2 Hz), 7.03 (1H, d, *J* = 8.8 Hz), 7.10–7.16 (6H, m), 7.28–7.34 (10H, m), 7.55 (1H, d, *J* = 8.8 Hz), 7.56 (1H, dd, *J* = 1.8, 9.0 Hz), 7.81 (1H, d, *J* = 9.0 Hz), 7.92 (1H, d, *J* = 1.8 Hz). IR (KBr): 3200, 2961, 1472, 1242, 839, 702 cm⁻¹. Anal. Calcd for C₄₃H₄₈N₂O₂Si: C, 79.10; H, 7.41; N, 4.29. Found: C, 79.11; H, 7.44; N,4.40.

5.24. 1-(6-{[*tert*-Butyl(dimethyl)silyl]oxy}-7-methyl-2-naphthyl)-2-methyl-1-(1-trityl-1*H*-imidazol-4-yl)-1-propanol (18d)

Yield 93%, pale yellow powder. ¹H NMR (CDCl₃) δ : 0.27 (6H, s), 0.75 (3H, d, *J* = 6.6 Hz), 0.94 (3H, d, *J* = 6.6 Hz), 1.05 (9H, s), 2.35 (3H, s), 2.45–2.58 (1H, m), 3.67 (1H, s), 6.80 (1H, d, *J* = 1.2 Hz), 7.06 (1H, s), 7.11–7.15 (6H, m), 7.30–7.7.33 (10H, m), 7.44 (1H, dd, *J* = 1.8, 8.6 Hz), 7.53–7.57 (2H, m), 7.86 (1H, s). IR (KBr): 3198, 1472, 1445, 1250, 1163, 1124, 914, 700 cm⁻¹. Anal. Calcd for C₄₃H₄₈N₂O₂Si: C, 79.10; H, 7.41; N, 4.29. Found: C, 79.12; H, 7.39; N, 4.44.

5.25. 6-[1-Hydroxy-2-methyl-1-(1-trityl-1*H*-imidazol-4-yl)-propyl]-2-naphthol (19a)

Tetrabutylammonium fluoride (1 M in THF; 100 mL) was added to a cooled (0 °C) solution of **18a** (35.0 g, 54.8 mmol) in anhydrous THF (100 mL), and the reaction mixture was stirred for 1 h at rt. After removal of the solvent in vacuo, the residue was diluted with water. The precipitate was filtered, washed with water and AcOEt, and then dried in vacuo (100 °C) to give 19a (28.3 g, 98%) as a colorless powder. The analytical sample was obtained by recrystallization from THF-hexane (colorless powder). ¹H NMR (CDCl₃+ CD₃OD) δ : 0.76 (3H, d, J = 6.8 Hz), 0.95 (3H, d, J = 6.6 Hz), 2.27-2.71 (1H, m), 6.86 (1H, d, J = 1.4 Hz), 7.05-7.17 (7H, m), 7.31–7.38 (11H, m), 7.48 (1H, dd, J = 1.8, 8.6 Hz), 7.58 (1H, d, J = 8.8 Hz), 7.67 (1H, d, J = 8.6 Hz), 7.85 (1H, s). IR (KBr): 3598, 2965, 1603, 1445, 1250, 1223, 1171, 702 cm⁻¹. LCMS (API): *m/z* 523.1 [M-H]⁻. Anal. Calcd for C₃₆H₃₂N₂O₂·0.5H₂O·0.5THF: C, 80.11; H, 6.55; N, 4.92. Found: C, 80.27; H, 6.55, N, 4.92. Compounds **19b-d** were prepared using the same method as described for the preparation of **19a**.

5.26. Chloro-6-[1-hydroxy-2-methyl-1-(1-trityl-1*H*-imidazol-4-yl)propyl]-2-naphthol (19b)

Yield 89%, colorless powder. ¹H NMR (CDCl₃ + CD₃OD) δ : 0.73 (3H, d, *J* = 7.0 Hz), 0.97 (3H, d, *J* = 6.6 Hz), 2.48–2.61 (1H, m), 6.86

(1H, d, *J* = 1.4 Hz), 6.90 (1H, d, *J* = 9.2 Hz), 7.12–7.17 (6H, m), 7.31–7.47 (12H, m), 7.85 (1H, s), 7.94 (1H, d, *J* = 9.2 Hz). IR (KBr): 3533, 2971, 1485, 1350, 1310, 1001, 758, 702 cm⁻¹. LCMS (API): *m/z* 557.1 [M–H][–]. Anal. Calcd for $C_{36}H_{31}N_2O_2CI.0.5THF$: C, 76.69; H, 5.93; N, 4.71. Found: C, 76.51; H, 5.92; N, 4.62.

5.27. 6-[1-Hydroxy-2-methyl-1-(1-trityl-1*H*-imidazol-4-yl)-propyl]-1-methyl-2-naphthol (19c)

Yield 95%, colorless powder. ¹H NMR (CDCl₃) δ : 0.69 (3H, d, J = 6.6 Hz), 1.03 (3H, d, J = 6.6 Hz), 2.30–2.43 (1H, m), 2.43 (3H, s), 3.89 (1H, s), 6.04 (1H, d, J = 8.8 Hz), 6.49 (1H, d, J = 8.8 Hz), 6.65–6.93 (2H, m), 7.21–7.25 (6H, m), 7.37–7.48 (10H, m), 7.55 (1H, d, J = 8.8 Hz), 7.56 (1H, d, J = 1.0 Hz). IR (KBr): 3511, 2976, 1485, 1445, 1348, 1169, 1001, 758, 702 cm⁻¹. LCMS (API): m/z 539.1 [M+H]⁺. Anal. Calcd for C₃₇H₃₄N₂O₂·0.5THF: C, 81.50; H, 6.66; N, 4.87. Found: C, 81.54; H, 6.67; N, 4.82.

5.28. 6-[1-Hydroxy-2-methyl-1-(1-trityl-1*H*-imidazol-4-yl)-propyl]-3-methyl-2-naphthol (19d)

Yield 98%, colorless plates. ¹H NMR (DMSO- d_6) δ : 0.61 (3H, d, J = 6.8 Hz), 0.71 (3H, d, J = 6.6 Hz), 2.27 (3H, s), 2.54–2.64 (1H, m), 5.04 (1H, s), 6.83 (1H, d, J = 1.4 Hz), 7.03–7.08 (6H, m), 7.29 (1H, d, J = 1.4 Hz), 7.33–7.41 (10H, m), 7.45–7.50 (2H, m), 7.69 (1H, dd, J = 1.4, 8.8 Hz), 7.84 (1H, s), 9.26 (1H, br s). IR (KBr): 3603, 2966, 1670, 1447, 1244, 1159, 760, 748, 704 cm⁻¹. Anal. Calcd for C₃₇H₃₄N₂O₂·0.6DMF: C, 80.00; H, 6.61; N, 6.25. Found: C, 80.03; H, 6.59; N, 6.19.

5.29. 6-[1-Hydroxy-2-methyl-1-(1-trityl-1*H*-imidazol-4-yl)-propyl]-2-naphthyl trifluoromethanesulfonate (20a)

Trifluoromethanesulfonic anhydride (9.1 mL, 54.1 mmol) was added dropwise to a cooled (0 °C) solution of **19a** (27.0 g, 51.5 mmol) in anhydrous pyridine (200 mL) and stirred for 1 h at 0 °C. After dilution with water, the resulting mixture was extracted with AcOEt (\times 2). The combined organic layers were washed with brine, dried over MgSO₄, and then concentrated in vacuo. The residue was purified by column chromatography on silica gel (hexane/AcOEt = 1:1) and recrystallized from i-Pr₂O to give 23 (26.1 g, 77%) as a colorless powder. The mother liquor was concentrated, and the residue was recrystallized from *i*-Pr₂O to give **20a** (3.54 g, 10%) as a colorless powder. ¹H NMR (CDCl₃) δ : 0.73 (3H, d, J = 6.6 Hz), 0.96 (3H, d, J = 6.6 Hz), 2.47-2.60 (1H, m), 3.72 (1H, br s), 6.82 (1H, d, I = 1.4 Hz), 7.10–7.17 (6H, m), 7.30–7.35 (11H, m), 7.65 (1H, dd, J = 1.7, 8.6 Hz), 7.70 (1H, d, *I* = 2.6 Hz), 7.77 (1H, d, *I* = 8.6 Hz), 7.88 (1H, d, *I* = 9.0 Hz), 8.11 (1H, s). IR (KBr): 3164, 2965, 1431, 1412, 1242, 1211, 1142, 909, 897, 748, 702 cm⁻¹. Anal. Calcd for C₃₇H₃₁N₂O₄SF₃: C, 67.67; H, 4.76; N, 4.27. Found: C, 67.75; H, 4.51; N, 4.34. Compounds 20b-d were prepared using the same method as described for the preparation of **20a**.

5.30. 1-Chloro-6-[1-hydroxy-2-methyl-1-(1-trityl-1*H*-imidazol-4-yl)propyl]-2-naphthyl trifluoromethanesulfonate (20b)

Yield 94%, colorless powder. ¹H NMR (CDCl₃) δ : 0.72 (3H, d, J = 6.6 Hz), 0.97 (3H, d, J = 6.6 Hz), 2.48–2.61 (1H, m), 3.75 (1H, s), 6.82 (1H, d, J = 1.6 Hz), 7.09–7.16 (6H, m), 7.30–7.37 (10H, m), 7.40 (1H, d, J = 9.2 Hz), 7.75 (1H, dd, J = 1.8, 8.8 Hz), 7.81 (1H, d, J = 9.2 Hz), 8.15 (1H, d, J = 1.8 Hz), 8.19 (1H, d, J = 8.8 Hz). IR (KBr): 3194, 2965, 1422, 1221, 1134, 828, 702 cm⁻¹. Anal. Calcd for C₃₇H₃₀N₂O₄SCIF₃: C, 64.30; H, 4.37; N, 4.05. Found: C, 64.03; H, 4.19; N, 4.03.

5.31. 6-[1-Hydroxy-2-methyl-1-(1-trityl-1*H*-imidazol-4-yl)propyl]-1-methyl-2-naphthyl trifluoromethanesulfonate (20c)

Yield 61%, colorless powder. ¹H NMR (CDCl₃) δ : 0.73 (3H, d, J = 6.6 Hz), 0.96 (3H, d, J = 6.6 Hz), 2.48–2.63 (1H, m), 2.67 (3H, s), 3.70 (1H, s), 6.82 (1H, d, J = 1.4 Hz), 7.10–7.16 (6H, m), 7.29–7.35 (11H, m), 7.69–7.74 (2H, m), 7.95 (1H, d, J = 8.8 Hz), 8.07 (1H, d, J = 1.8 Hz). IR (KBr): 3208, 2973, 1408, 1219, 1140, 897, 702 cm ⁻¹. Anal. Calcd for C₃₈H₃₃N₂O₄SF₃: C, 68.05; H, 4.96; N, 4.18. Found: C, 68.22; H, 4.97; N, 4.19.

5.32. 6-[1-Hydroxy-2-methyl-1-(1-trityl-1*H*-imidazol-4-yl)propyl]-3-methyl-2-naphthyl trifluoromethanesulfonate (20d)

Yield 74%, yellow powder. ¹H NMR (CDCl₃) δ : 0.72 (3H, d, J = 7.0 Hz), 0.96 (3H, d, J = 7.0 Hz), 2.46–2.59 (1H, m), 2.51 (3H, s), 3.72 (1H, s), 6.80 (1H, d, J = 1.6 Hz), 7.09–7.16 (6H, m), 7.29–7.36 (10H, m), 7.56 (1H, dd, J = 1.8, 8.6 Hz), 7.67–7.73 (3H, m), 8.02 (1H, s). IR (KBr): 3219, 2966, 1408, 1215, 1140, 1055, 895, 748, 700 cm⁻¹. Anal. Calcd for C₃₈H₃₃N₂O₄SF₃: C, 68.05; H, 4.96; N, 4.18. Found: C, 68.16; H, 4.98; N, 4.01.

5.33. Methyl-6-[1-hydroxy-2-methyl-1-(1-trityl-1*H*-imidazol-4-yl)propyl]-2-naphthoate (21a)

A degassed solution of 20a (15.0 g, 22.8 mmol) and triethylamine (6.36 mL, 45.6 mmol) in anhydrous DMF (90 mL) and MeOH (30 mL) was added to Pd(OAc)₂ (256 mg, 1.14 mmol) and dppf (632 mg, 1.14 mmol), and vigorously stirred for 14 h at 70 °C under CO atmosphere (1 atm). After dilution with water, the resulting mixture was extracted with AcOEt ($\times 2$). The combined organic layers were washed with water and brine, and then dried over MgSO₄. After removal of the solvent in vacuo, the residue was purified by column chromatography on silica gel (hexane/THF = 1:2) and recrystallized from hexane-AcOEt to give 21a (12.3 g, 95%) as a light brown powder. ¹H NMR (CDCl₃) δ : 0.74 (3H, d, J = 7.0 Hz), 0.97 (3H, d, J = 6.6 Hz), 2.47-2.61 (1H, m), 3.75 (1H, s), 3.97 (3H, s), 6.82 (1H, d, J = 1.2 Hz), 7.10–7.16 (6H, m), 7.29–7.35 (10H, m), 7.62 (1H, dd, J = 1.8, 8.6 Hz), 7.81 (1H, d, J = 3.2 Hz), 7.85 (1H, d, J = 3.2 Hz), 8.02 (1H, dd, J = 1.8 Hz, 8.6 Hz), 8.07 (1H, s), 8.55 (1H, s). IR (KBr): 3542, 2965, 1707, 1441, 1279, 1231, 747, 700 cm⁻¹. Anal. Calcd for C₃₈H₃₄N₂O₃·0.1AcOEt: C, 80.41; H, 6.09; N, 4.87. Found: C, 80.07; H, 6.06; N, 4.95. Compounds **21b–d** were prepared using the same method as described for the preparation of **21a**.

5.34. Methyl-1-chloro-6-[1-hydroxy-2-methyl-1-(1-trityl-1*H*-imidazol-4-yl)propyl]-2-naphthoate (21b)

Yield 89%, colorless powder. ¹H NMR (CDCl₃) δ : 0.72 (3H, d, J = 7.0 Hz), 0.97 (3H, d, J = 6.0 Hz), 2.44–2.61 (1H, m), 3.79 (1H, s), 3.98 (3H, s), 6.82 (1H, d, J = 1.4 Hz), 7.09–7.14 (6H, m), 7.31–7.38 (10H, m), 7.70 (1H, dd, J = 1.8, 9.0 Hz), 7.75 (s, 2H), 8.09 (1H, d, J = 1.4 Hz), 8.34 (1H, d, J = 9.2 Hz). IR (KBr): 3162, 1732, 1240, 1012, 747, 700 cm⁻¹. Anal. Calcd for C₃₈H₃₃N₂O₃Cl: C, 75.92; H, 5.53; N, 4.66. Found: C, 75.88; H, 5.58; N, 4.65.

5.35. Methyl-6-[1-hydroxy-2-methyl-1-(1-trityl-1*H*-imidazol-4-yl)propyl]-1-methyl-2-naphthoate (21c)

Yield 81%, colorless powder. ¹H NMR (CDCl₃) δ : 0.74 (3H, d, J = 7.0 Hz), 0.76 (3H, d, J = 6.0 Hz), 2.48–2.62 (1H, m), 2.91 (3H, s), 3.74 (1H, s), 3.94 (3H, s), 6.82 (1H, d, J = 1.4 Hz), 7.10–7.15 (6H, m), 7.30–7.34 (10H, m), 7.64–7.70 (2H, m), 7.80 (1H, d, J = 8.8 Hz), 8.02 (1H, d, J = 1.4 Hz), 8.08 (1H, d, J = 9.2 Hz). IR (KBr): 3162, 2969, 1719, 1445, 1240, 1173, 747, 700 cm⁻¹. Anal.

Calcd for $C_{39}H_{36}N_2O_3$: C, 80.66; H, 6.25; N, 4.82. Found: C, 80.47; H, 6.26; N, 4.72.

5.36. Methyl-6-[1-hydroxy-2-methyl-1-(1-trityl-1*H*-imidazol-4-yl)propyl]-3-methyl-2-naphthoate (21d)

Yield 88%, pale yellow powder. ¹H NMR (CDCl₃) δ : 0.73 (3H, d, J = 6.8 Hz), 0.95 (3H, d, J = 6.6 Hz), 2.45–2.59 (1H, m), 2.71 (3H, s), 3.73 (1H, s), 3.94 (3H, s), 6.80 (1H, d, J = 1.6 Hz), 7.10–7.16 (6H, m), 7.29–7.36 (10H, m), 7.54 (1H, dd, J = 1.6, 8.6 Hz), 7.61 (1H, s), 7.76 (1H, d, J = 8.6 Hz), 7.96 (1H, s), 8.44 (1H, s). IR (KBr): 3223, 2968, 1724, 1445, 1283, 1267, 748, 700 cm⁻¹. Anal. Calcd for C₃₉H₃₆N₂O₃·0.4AcOEt: C, 79.17; H, 6.41; N, 4.55. Found: C, 79.17; H, 6.23; N, 4.61.

5.37. Methyl 6-[1-hydroxy-1-(1*H*-imidazol-4-yl)-2-methylpropyl]-2-naphthoate (22)

Compound **21a** (1.40 g, 2.47 mmol) was used as a starting material. Using the same procedure described for the synthesis of **6**, **22** (751 mg, 94%) was obtained as a pale yellow powder after recrystallization from AcOEt. Mp 167.0–169.0 °C. ¹H NMR (CDCl₃ + CD₃OD) δ : 0.80 (3H, d, *J* = 7.0 Hz), 1.02 (3H, d, *J* = 6.6 Hz), 2.69–2.82 (1H, m), 3.97 (3H, s), 7.02 (1H, d, *J* = 1.2 Hz), 7.52 (1H, d, *J* = 1.2 Hz), 7.68 (1H, dd, *J* = 1.0, 8.4 Hz), 7.87 (2H, d, *J* = 8,4 Hz), 8.01 (1H, dd, *J* = 1.0, 8.4 Hz), 8.08 (1H, s), 8.55 (1H, s). IR (KBr): 3542, 2965, 1707, 1441, 1279, 1231, 747, 700 cm⁻¹. LCMS (API): *m/z* 325.1 [M+H]⁺. Anal. Calcd for C₁₉H₂₀N₂O₃·0.2AcOEt: C, 69.54; H, 6.37; N, 8.19. Found: C, 69.53; H, 6.43; N, 8.26.

5.38. 6-[1-Hydroxy-2-methyl-1-(1-trityl-1*H*-imidazol-4-yl)-propyl]-2-naphthamide (23a)

A solution of 21a (2.0 g, 3.53 mmol) in THF (20 mL) and MeOH (4 mL) and 4 N NaOH (4 mL) was stirred for 2 h at 60 °C. After cooling to 0 °C, the solution was neutralized with concentrated HCl and extracted with AcOEt (\times 2). The combined organic layers were washed with brine and concentrated in vacuo. The residue was dried with toluene azeotropically $(\times 2)$ to give the carboxylate as a light brown powder, which was used for the next reaction without further purification. A mixture of the carboxylate, ammonium bicarbonate (558 mg, 7.06 mmol), DPPA (0.91 mL, 4.24 mmol) and triethylamine (0.98 mL, 7.06 mmol) in anhydrous DMF (10 mL) was stirred for 12 h at rt. After dilution with water, the mixture was extracted with AcOEt ($\times 2$). The combined organic layers were washed with water and brine, and then dried over MgSO₄. After removal of the solvent in vacuo, the residue was purified by column chromatography on silica gel (hexane/THF = 1:2) and washed with hexane-AcOEt to give 23a (1.96 g, quant.) as a colorless powder. The analytical sample was obtained by recrystallizaion from THF-hexane (colorless powder). ¹H NMR (CDCl₃+ CD₃OD) δ : 0.74 (3H, d, J = 7.0 Hz), 0.97 (3H, d, J = 7.0 Hz), 2.55-2.68 (1H, m), 6.86 (1H, d, J=1.2 Hz), 7.09-7.14 (6H, m), 7.27–2.38 (10H, m), 7.63 (1H, d, J = 1.7, 8.5 Hz), 7.82–7.85 (3H, m), 8.04 (1H, s), 8.33 (1H, s). IR (KBr): 3407, 3189, 2965, 1644, 1443, 748, 700 cm⁻¹. Anal. Calcd for C₃₇H₃₃N₃O₂·1.0THF: C, 78.94; H, 6.62; N, 6.74. Found: C, 78.83; H, 6.57; N, 6.94.

5.39. General procedure for the synthesis of the carbamoyl derivatives: 6-[1-hydroxy-2-methyl-1-(1-trityl-1*H*-imidazol-4-yl)propyl]-*N*-methyl-2-naphthamide (23b)

Using the same procedure as described for the synthesis of **23a**, **21a** (8.0 g, 14.1 mmol) was hydrolyzed to give the carboxylate (light brown powder). A solution of the carboxylate, methylamine (2 M solution in THF; 8.45 mL), EDCI·HCl (3.24 g, 16.9 mmol),

HOBt H₂O (2.59 g, 16.9 mmol) and triethylamine (2.36 mL, 16.9 mmol) in anhydrous DMF (80 mL) was stirred for 12 h at rt. After dilution with water, the mixture was extracted with AcOEt $(\times 2)$. The combined organic layers were washed with water and brine, and then dried over MgSO₄. After removal of the solvent in vacuo, the residue was washed with AcOEt to give 23b (8.0 g, quant.) as a pale yellow powder. The analytical sample was obtained by recrystallization from THF-hexane (pale yellow powder). ¹H NMR (CDCl₃ + CD₃OD) δ : 0.75 (3H, d, J = 6.6 Hz), 0.97 (3H, d, *I* = 7.0 Hz), 2.60–2.74 (1H, m), 3.01 (3H, d, *J* = 4.4 Hz), 6.89 (1H, s), 7.10-7.14 (6H, m), 7.27-7.38 (10H, m), 7.65 (1H, dd, J=1.4, 8.8 Hz), 7.82-7.86 (3H, m), 8.03 (1H, s), 8.28 (1H, s). IR (KBr): 3345, 2969, 1657, 1443, 1302, 1011, 747, 700 cm⁻¹. Anal. Calcd for C38H35N3O2.0.3THF: C, 80.03; H, 6.58; N, 7.14. Found: C, 79.81; H, 6.46; N, 7.05. Compounds 23c-h were prepared using the same method as described for the preparation of **23b**.

5.40. *N*-Ethyl-6-[1-hydroxy-2-methyl-1-(1-trityl-1*H*-imidazol-4-yl)propyl]-2-naphthamide (23c)

Yield 83%, colorless powder. ¹H NMR (CDCl₃) δ : 0.73 (3H, d, J = 3.3 Hz), 0.96 (3H, d, J = 6.6 Hz), 1.28 (3H, t, J = 7.2 Hz), 2.47–2.60 (1H, m), 3.48–3.61 (2H, m), 3.79 (1H, s), 6.32 (1H, t, J = 5.5 Hz), 6.82 (1H, d, J = 1.4 Hz), 7.09–7.16 (6H, m), 7.28–7.34 (10H, m), 7.61 (1H, dd, J = 1.8, 8.8 Hz), 7.75–7.84 (3H, m), 8.05 (1H, s), 8.23 (1H, s). IR (KBr): 3308, 2967, 1638, 1535, 1308, 1009, 747, 700 cm⁻¹. Anal. Calcd for C₃₉H₃₇N₃O₂-0.1AcOEt: C, 80.41; H, 6.47; N, 7.14. Found: C, 80.26; H, 6.54; N, 7.09.

5.41. 6-[1-Hydroxy-2-methyl-1-(1-trityl-1*H*-imidazol-4-yl)-propyl]-*N*-propyl-2-naphthamide (23d)

Yield 92%, colorless powder. ¹H NMR (CDCl₃) δ: 0.73 (3H, d, J = 6.8 Hz), 0.96 (3H, d, J = 6.8 Hz), 1.02 (3H, t, J = 7.2 Hz), 1.60–1.78 (2H, m), 2.53 (1H, quintet, J = 6.8 Hz), 3.48 (2H, q, J = 7.2 Hz), 3.76 (1H, s), 6.28 (1H, t, J = 7.2 Hz), 6.81 (1H, d, J = 1.4 Hz), 7.07–7.20 (6H, m), 7.28–7.37 (10H, m), 7.62 (1H, dd, J = 1.8, 8.6 Hz), 7.75–7.86 (3H, m), 8.06 (1H, s), 8.23 (1H, s). IR (KBr): 3326, 2967, 1642, 1599, 1541, 1445, 1308, 1157 cm⁻¹. Anal. Calcd for C₄₀H₃₉N₃O₂: C, 80.91; H, 6.62; N, 7.08. Found: C 80.84; H, 6.86; N, 7.08.

5.42. 6-[1-Hydroxy-2-methyl-1-(1-trityl-1*H*-imidazol-4-yl)propyl]-*N*-isopropyl-2-naphthamide (23e)

Yield 91%, colorless powder. ¹H NMR (CDCl₃) δ : 0.73 (3H, d, J = 6.8 Hz), 0.96 (3H, d, J = 6.8 Hz), 1.31 (6H, d, J = 6.6 Hz), 2.53 (1H, quintet, J = 6.8 Hz), 3.76 (1H, s), 4.27–4.43 (1H, m), 6.06 (1H, d, J = 7.4 Hz), 6.81 (1H, d, J = 1.4 Hz), 7.07–7.18 (6H, m), 7.28–7.38 (10H, m), 7.61 (1H, dd, J = 1.8, 8.6 Hz), 7.74–7.85 (3H, m), 8.06 (1H, s), 8.22 (1H, s). IR (KBr): 3301, 2971, 1640, 1601, 1537, 1447, 1289, 1171 cm⁻¹. Anal. Calcd for C₄₀H₃₉N₃O₂·0.25H₂O: C, 81.30; H, 6.65; N, 7.02. Found: C, 80.33; H, 6.68; N, 6.88.

5.43. 1-Chloro-6-[1-hydroxy-2-methyl-1-(1-trityl-1*H*-imidazol-4-yl)propyl]-*N*-methyl-2-naphthamide (23f)

Yield 75%, colorless powder. ¹H NMR (CDCl₃) δ : 0.71 (3H, d, J = 7.0 Hz), 0.96 (3H, d, J = 6.6 Hz), 2.46–2.60 (1H, m), 3.07 (3H, d, J = 4.8 Hz), 3.81 (1H, s), 6.24 (1H, d, J = 4.8 Hz), 6.82 (1H, d, J = 0.6 Hz), 7.09–7.14 (6H, m), 7.31–7.34 (10H, m), 7.57 (1H, d, J = 8.4 Hz), 7.69–7.73 (2H, m), 8.05 (1H, s), 8.22 (1H, d, J = 8.8 Hz). IR (KBr): 3376, 2969, 1634, 1157, 1134, 702 cm⁻¹. Anal. Calcd for C₃₈H₃₄N₃O₂Cl: C, 76.05; H, 5.71; N, 7.00. Found: C, 75.87; H, 5.71; N, 6.97.

5.44. 6-[1-Hydroxy-2-methyl-1-(1-trityl-1*H*-imidazol-4-yl)-propyl]-*N*,1-dimethyl-2-naphthamide (23g)

Yield 95%, colorless powder. ¹H NMR (CDCl₃) δ : 0.72 (3H, d, J = 6.6 Hz), 0.95 (3H, d, J = 6.6 Hz), 2.47–2.61 (1H, m), 2.70 (3H, s), 3.02 (3H, d, J = 4.8 Hz), 3.75 (1H, s), 5.89 (1H, br s), 6.81 (1H, d, J = 1.2 Hz), 7.09–7.14 (6H, m), 7.28–7.35 (10H, m), 7.59–7.68 (2H, m), 7.93–7.99 (2H, m). IR (KBr): 3407, 3250, 2971, 1634, 1495, 1157, 816, 702 cm⁻¹. Anal. Calcd for C₃₉H₃₇N₃O₂: C, 80.80; H, 6.43; N, 7.25. Found: C, 80.41; H, 6.33; N, 7.18.

5.45. 6-[1-Hydroxy-2-methyl-1-(1-trityl-1*H*-imidazol-4-yl)-propyl]-*N*,3-dimethyl-2-naphthamide (23h)

Yield 86%, colorless powder. ¹H NMR (CDCl₃ + CD₃OD) δ : 0.72 (3H, d, *J* = 6.6 Hz), 0.95 (3H, d, *J* = 6.6 Hz), 2.54 (3H, s), 2.52–2.65 (1H, m), 2.99 (3H, d, *J* = 4.0 Hz), 6.85 (1H, d, *J* = 1.6 Hz), 7.10–7.15 (6H, m), 7.32–7.38 (10H, m), 7.53 (1H, dd, *J* = 1.6, 8.6 Hz), 7.58 (1H, s), 7.69 (1H, d, *J* = 8.6 Hz), 7.78 (1H, s), 7.89 (1H, s). IR (KBr): 3412, 3277, 2966, 1645, 1011, 746, 702 cm⁻¹. Anal. Calcd for C₃₉H₃₇N₃O₂·0.1AcOEt: C, 80.41; H, 6.47; N, 7.14. Found: C, 80.36; H, 6.31; N, 7.14. Compounds **24a–h** were prepared using the method as described for the preparation of **6**.

5.46. 6-[1-Hydroxy-1-(1*H*-imidazol-4-yl)-2-methylpropyl]-2-naphthamide (24a)

Yield 88%, a colorless amorphous solid. ¹H NMR (CDCl₃ + CD₃OD) δ : 0.78 (3H, d, *J* = 6.6 Hz), 1.00 (3H, d, *J* = 7.0 Hz), 2.66–2.80 (1H, m), 7.00 (1H, d, *J* = 1.0 Hz), 7.49 (1H, d, *J* = 1.0 Hz), 7.63 (1H, d, *J* = 1.8, 8.8 Hz), 7.77–7.81 (3H, m), 8.04 (1H, s), 8.29 (1H, s). IR (KBr): 3200, 2969, 1659, 1393, 816 cm⁻¹. LCMS (API): *m/z* 310.1 [M+H]⁺. Anal. Calcd for C₁₈H₁₉N₃O₂·H₂O: C, 66.04; H, 6.47; N, 12.84. Found: C, 66.65; H, 6.45; N, 12.86.

5.47. 6-[1-Hydroxy-1-(1*H*-imidazol-4-yl)-2-methylpropyl]-*N*-methyl-2-naphthamide (24b)

Yield 88%, colorless powder. Mp 217.0–219.0 °C. ¹H NMR (CDCl₃ + CD₃OD) δ : 0.78 (3H, d, *J* = 7.0 Hz), 1.01 (3H, d, *J* = 6.6 Hz), 2.67–2.80 (1H, m), 3.00 (3H, s), 7.00 (1H, d, *J* = 1.2 Hz), 7.49 (1H, d, *J* = 1.0 Hz), 7.63 (1H, dd, *J* = 1.8, 8.8 Hz), 7.74–7.79 (2H, m), 7.83 (1H, d, *J* = 8.4 Hz), 8.03 (1H, s), 8.22 (1H, s). ¹³C NMR (DMSO-*d*₆) δ : 16.7, 17.4, 26.3, 36.6, 77.4, 112.0, 123.1, 123.8, 125.9, 126.7, 127.5, 127.9, 130.6, 131.1, 133.6, 134.2, 147.2, 147.5, 166.7. IR (KBr): 3565, 3351, 3318, 2973, 1638, 1628, 1549, 1308, 993, 812 cm⁻¹. LCMS (API): *m/z* 324.2 [M+H]⁺. Anal. Calcd for C₁₉H₂₁N₃O₂: C, 70.57; H, 6.55; N, 12.99. Found: C, 70.46; H, 6.67; N, 12.87.

5.48. *N*-Ethyl-6-[1-Hydroxy-1-(1*H*-imidazol-4-yl)-2-methylpro-pyl]-2-naphthamide (24c)

Yield 92%, pale yellow amorphous solid. ¹H NMR (CDCl₃ + CD₃OD) δ : 0.77 (3H, d, *J* = 7.0 Hz), 1.00 (3H, d, *J* = 7.0 Hz), 1.26 (3H, t, *J* = 7.2 Hz), 2.63–2.77 (1H, m), 3.42–3.56 (2H, m), 6.98 (1H, d, *J* = 1.2 Hz), 7.22 (1H, t, *J* = 5.5 Hz), 7.44 (1H, d, *J* = 1.2 Hz), 7.59 (1H, dd, *J* = 1.6, 8.6 Hz), 7.70–7.76 (3H, m), 8.01 (1H, s), 8.19 (1H, s). IR (KBr): 3310, 2971, 1638, 1561, 1306, 1146, 816 cm⁻¹. LCMS (API): *m/z* 338.2 [M+H]⁺. Anal. Calcd for C₂₀H₂₃N₃O₂·0.75H₂O: C, 68.45; H, 7.04; N, 11.97. Found: C, 68.62; H, 7.08; N, 11.93.

5.49. 6-[1-Hydroxy-1-(1*H*-imidazol-4-yl)-2-methylpropyl]-*N*-propyl-2-naphthamide (24d)

Yield 77%, colorless amorphous powder solid. ¹H NMR (CDCl₃) δ : 0.78 (3H, d, *J* = 6.6 Hz), 1.00 (3H, t, *J* = 7.2 Hz), 1.00 (3H, d,

J = 6.6 Hz), 1.58–1.77 (2H, m), 2.68 (1H, quintet, *J* = 7.2 Hz), 3.40– 3.52 (2H, m), 3.49 (1H, s), 6.44 (1H, t, *J* = 5.5 Hz), 6.99 (1H, s), 7.45 (1H, s), 7.59–7.80 (4H, m), 8.05 (1H, s), 8.1 7 (1H, s). IR (KBr): 3400–3100, 2967, 1640, 1601, 1539, 1464, 1308, 1144 cm $^{-1}$. LCMS (API): *m/z* 352.3 [M+H]⁺. Anal. Calcd for C₂₁H₂₅N₃O₂·0.2H₂O: C, 71.04; H, 7.21; N, 11.83. Found: C, 70.83; H, 7.29; N, 11.78.

5.50. 6-[1-Hydroxy-1-(1*H*-imidazol-4-yl)-2-methylpropyl]-*N*-isopropyl-2-naphthamide (24e)

Yield 73%, colorless amorphous solid. ¹H NMR (CDCl₃) δ : 0.77 (3H, d, *J* = 6.8 Hz), 1.00 (3H, d, *J* = 6.8 Hz), 1.29 (6H, d, *J* = 6.6 Hz), 2.67 (1H, quintet, *J* = 6.8 Hz), 3.48 (1H, s), 4.26–4.42 (1H, m), 6.23 (1H, d, *J* = 7.8 Hz), 6.97 (1H, d, *J* = 1.2 Hz), 7.41 (1H, d, *J* = 1.2 Hz), 7.57–7.80 (4H, m), 8.04 (1H, s), 8.14 (1H, s). IR (KBr): 3400–3100, 2973, 1626, 1601, 1537, 1456, 1294, 1173 cm⁻¹. LCMS (API): *m/z* 352.3 [M+H]⁺. Anal. Calcd for C₂₁H₂₅N₃O₂·0.15H₂O: C, 71.22; H, 7.20; N, 11.87. Found: C, 71.05; H, 7.34; N, 11.81.

5.51. 1-Chloro-6-[1-hydroxy-1-(1*H*-imidazol-4-yl)-2-methyl-propyl]-*N*-methyl-2-naphthamide (24f)

Yield 93%, pale yellow amorphous solid. ¹H NMR (CDCl₃ + CD₃OD) δ : 0.76 (3H, d, *J* = 6.6 Hz), 0.99 (3H, d, *J* = 6.6 Hz), 2.64–2.78 (1H, m), 3.01 (3H, d, *J* = 1.4 Hz), 6.98 (1H, s), 7.41 (1H, dd, *J* = 1.4, 8.6 Hz), 7.42 (1H, s), 7.69 (1H, d, *J* = 7.8 Hz), 7.72 (1H, dd, *J* = 1.4, 7.8 Hz), 8.01 (1H, s), 8.19 (1H, d, *J* = 8.6 Hz). IR (KBr): 3242, 2970, 1630, 1553, 1333, 824 cm⁻¹. LCMS (API): *m/z* 358.1 [M+H]⁺. Anal. Calcd for C₁₉H₂₀N₃O₂·0.5H₂O: C, 62.21; H, 5.77; N, 11.45. Found: C, 62.10; H, 5.84; N, 11.37.

5.52. 6-[1-Hydroxy-1-(1*H*-imidazol-4-yl)-2-methylpropyl]-*N*,1dimethyl-2-naphthamide (24g)

Yield 91%, colorless amorphous solid. ¹H NMR (CDCl₃ + CD₃OD) δ : 0.78 (3H, d, *J* = 7.0 Hz), 0.99 (3H, d, *J* = 6.6 Hz), 2.65 (3H, s), 2.65–2.78 (1H, m), 2.98 (3H, s), 6.97 (1H, d, *J* = 1.2 Hz), 7.31 (1H, d, *J* = 8.4 Hz), 7.42 (1H, d, *J* = 1.2 Hz), 7.61–7.67 (2H, m), 7.93–7.97 (2H, m). IR (KBr): 330, 2975, 1634, 1559, 1410, 1159, 822 cm⁻¹. LCMS (API): *m/z* 338.2 [M+H]⁺. Anal. Calcd for C₂₀H₂₃N₃O₂·0.75H₂O: C, 68.45; H, 7.04; N, 11.97. Found: C, 68.20; H, 7.15; N, 11.83.

5.53. 6-[1-Hydroxy-1-(1*H*-imidazol-4-yl)-2-methylpropyl]-*N*,3-dimethyl-2-naphthamide (24h)

Yield 84%, pale yellow amorphous solid. ¹H NMR (CDCl₃ + CD₃OD) δ : 0.77 (3H, d, *J* = 7.0 Hz), 0.99 (3H, d, *J* = 6.6 Hz), 2.48 (3H, s), 2.61–2.74 (1H, m), 2.98 (3H, d, *J* = 3.0 Hz), 6.95 (1H, d, *J* = 1.2 Hz), 7.37 (1H, d, *J* = 1.2 Hz), 7.50 (1H, dd, *J* = 1.8, 8.8 Hz), 7.54 (1H, s), 7.64 (1H, d, *J* = 8.8 Hz), 7.72 (1H, s), 7.88 (1H, s). IR (KBr): 3192, 2968, 1643, 1539, 1408, 1304, 1155, 908, 818 cm⁻¹. LCMS (API): *m/z* 338.2 [M+H]⁺. Anal. Calcd for C₂₀H₂₃-N₃O₂·0.75H₂O: C, 68.45; H, 7.04; N, 11.97. Found: C, 68.56; H, 7.12; N, 11.79.

5.54. Methyl-1-(Bromomethyl)-6-[1-hydroxy-2-methyl-1-(1-triphenylmethyl-1*H*-imidazol-4-yl)propyl]-2-naphthoate (25)

A mixture of **21c** (34.61 g, 59.6 mmol), *N*-bromosuccinimide (12.28 g, 69.0 mmol) and 2,2'-azobisisobutyronitrile (0.99 g, 6.0 mmol) in CCl₄ (800 mL) was refluxed for 21 h. After removing the solvent, the mixture was diluted with aq NaHCO₃ solution. The resulting mixture was extracted with AcOEt–THF and the combined organic layers were washed with brine, dried over MgSO₄,

and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (AcOEt) to give a crude mixture of **21c** and **25** (**21c**:**25** = 1:7, 23.1 g, 59%). The analytical sample was obtained by recrystallization from THF–AcOEt as a colorless powder. Mp 195 °C decomp. ¹H NMR (CDCl₃) δ : 0.74 (3H, d, *J* = 6.8 Hz), 0.98 (3H, d, *J* = 6.8 Hz), 2.55 (1H, septet, *J* = 6.8 Hz), 3.78 (1H, s), 3.99 (3H, s), 5.43 (1H, d, *J* = 9.8 Hz), 5.47 (1H, d, *J* = 9.8 Hz), 6.82 (1H, d, *J* = 1.4 Hz), 7.10–7.35 (16H, m), 7.72 (1H, dd, *J* = 8.8, 1.8 Hz), 7.81 (1H, d, *J* = 8.8 Hz), 7.92 (1H, d, *J* = 8.8 Hz), 8.10 (1H, d, *J* = 1.8 Hz), 8.18 (1H, d, *J* = 8.8 Hz). IR (KBr): 1725, 1238, 702 cm⁻¹. Anal. Calcd for C₃₉H₃₅N₂O₃Br: C, 71.01; H, 5.35; N, 4.25; Br, 12.11. Found: C, 70.86; H, 5.42; N, 4.19.

5.55. 7-[1-Hydroxy-2-methyl-1-(1-triphenylmethyl-1*H*-imidazol-4-yl)propyl]-1,2-dihydro-3*H*-benzo[*e*]isoindol-3-one (26a)

A solution of saturated NH₃ in MeOH (50 mL) was added to a cooled (0 °C) solution of **25** (5.58 g, crude 8.5 mmol) in THF (50 mL), and stirred for 1 h at rt. After removal of the solvent, the residue was diluted with aq NaHCO₃ solution. The resulting mixture was extracted with AcOEt–THF and the combined organic layers were washed with brine, dried over MgSO₄, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (AcOEt/MeOH = 20:1) to give **26a** (1.22 g, 26%) as a colorless powder. Mp 250 °C decomp. ¹H NMR (CDCl₃ + CD₃OD) δ : 0.74 (3H, d, *J* = 6.6 Hz), 0.98 (3H, d, *J* = 6.6 Hz), 2.59 (1H, septet, *J* = 6.6 Hz), 4.73 (2H, s), 6.85 (1H, s), 7.10–7.38 (16H, m), 7.78–7.90 (4H, m), 8.11 (1H, s). IR (KBr): 1690, 745, 702 cm⁻¹. Anal. Calcd for C₃₈H₃₃N₃O₂·0.5H₂O: C, 79.69; H, 5.98; N, 7.34. Found: C, 79.57; H, 6.27; N, 7.07.

5.56. 7-[1-Hydroxy-2-methyl-1-(1-triphenylmethyl-1*H*-imidazol-4-yl)propyl]-2-methyl-1,2-dihydro-3*H*-benzo[*e*]isoindol-3one (26b)

Using **25** (0.80 g, 1.2 mmol) was used as the starting material and the same procedure described for the synthesis of **26a** with 40% methylamine solution, **26b** (0.77 g, quant.) was obtained as a colorless powder. The analytical sample was obtained by recrystallization from THF as a colorless powder. Mp 250 °C decomp. ¹H NMR (CDCl₃) δ : 0.74 (3H, d, *J* = 6.6 Hz), 0.97 (3H, d, *J* = 6.6 Hz), 2.56 (1H, septet, *J* = 6.6 Hz), 3.29 (3H, s), 3.69 (1H, br s), 4.68 (2H, s), 6.83 (1H, d, *J* = 1.4 Hz), 7.10–7.36 (16H, m), 7.76 (2H, s), 7.83 (2H, s), 8.11 (1H, s). IR (KBr): 3409, 1680, 704 cm⁻¹. Anal. Calcd for C₃₉H₃₅N₃O₂: C, 81.08; H, 6.11; N, 7.27. Found: C, 80.69; H, 6.11; N, 7.12.

5.57. 7-[1-Hydroxy-1-(1*H*-imidazol-4-yl)-2-methylpropyl]-1,2dihydro-3*H*-benzo[*e*]isoindol-3-one (27a)

Compound **26a** (1.17 g, 2.1 mmol) was used as a starting material. Using the same procedure described for the synthesis of **6**, **27a** (0.50 g, 75%) was obtained as a colorless powder. The analytical sample was obtained by recrystallization from EtOH–H₂O as a colorless powder. Mp 230 °C decomp. ¹H NMR (CDCl₃ + CD₃OD) δ : 0.79 (3H, d, *J* = 6.6 Hz), 1.02 (3H, d, *J* = 6.6 Hz), 2.76 (1H, septet, *J* = 6.6 Hz), 4.68 (2H, s), 7.04 (1H, s), 7.55 (1H, s), 7.70–7.77 (3H, m), 7.88 (1H, d, *J* = 8.4 Hz), 8.15 (1H, s). IR (KBr): 1684, 1472, 747 cm⁻¹. LCMS (API): *m/z* 322.1 [M+H]⁺. Anal. Calcd for C₁₉H₁₉N₃O₂: C, 71.01; H, 5.96; N, 13.08. Found: C, 70.76; H, 6.04; N, 12.78.

5.58. 7-[1-Hydroxy-1-(1*H*-imidazol-4-yl)-2-methylpropyl]-2-methyl-1,2-dihydro-3*H*-benzo[*e*]isoindol-3-one (27b)

Using **26b** was used as the starting material and the same procedure as described for the synthesis of **27a**, **27b** (0.28 g, 90%) was

obtained as a colorless powder. The analytical sample was obtained by recrystallization from THF–MeOH (colorless powder). Mp 250 °C decomp. ¹H NMR (CDCl₃ + CD₃OD) δ : 0.80 (3H, d, J = 7.0 Hz), 1.02 (3H, d, J = 7.0 Hz), 2.78 (1H, septet, J = 7.0 Hz), 3.29 (3H, s), 4.73 (2H, s), 7.04 (1H, d, J = 1.2 Hz), 7.54 (1H, d, J = 1.2 Hz), 7.76–7.94 (4H, m), 8.17 (1H, s). ¹³C NMR (DMSO- d_6) δ : 16.7, 17.4, 29.0, 36.7, 50.6, 77.4, 112.0, 119.0, 122.5, 124.3, 125.9, 126.5, 128.6, 129.0, 133.9, 134.2, 140.5, 147.1, 147.7, 168.1. IR (KBr): 3193, 1667, 1003 cm⁻¹. LCMS (API): m/z 336.2 [M+H]⁺. Anal. Calcd for C₂₀H₂₁N₃O₂·0.1H₂O: C, 71.24; H, 6.34; N, 12.46. Found: C, 71.09; H, 6.48; N, 12.23.

5.59. Methyl-3-(bromomethyl)-6-[1-hydroxy-2-methyl-1-(1-triphenylmethyl-1*H*-imidazol-4-yl)propyl]-2-naphthoate (28)

Using **21d** (5.93 g, 10.2 mmol) as the starting material and the same procedure as described for the synthesis of **25**, crude **28** (6.70 g, quant.) was obtained as a brown amorphous solid. ¹H NMR (CDCl₃) δ : 0.73 (3H, d, *J* = 6.6 Hz), 0.97 (3H, d, *J* = 6.6 Hz), 2.53 (1H, septet, *J* = 6.6 Hz), 3.74 (1H, s), 4.00 (3H, s), 5.12 (1H, d, *J* = 10.4 Hz), 5.15 (1H, d, *J* = 10.4 Hz), 6.81 (1H, d, *J* = 1.0 Hz), 7.09–7.38 (16H, m), 7.65 (1H, dd, *J* = 8.4, 1.6 Hz), 7.78–7.84 (2H, m), 8.02 (1H, s), 8.50 (1H, s). IR (KBr): 2969, 1717, 1287, 702 cm⁻¹. Anal. Calcd C₃₉H₃₅N₂O₃Br·2H₂O: C, 67.34; H, 5.65; N, 4.03; Br, 12.11.Found: C, 67.38; H, 5.50; N, 4.34.

5.60. 6-[1-Hydroxy-1-(1*H*-imidazol-4-yl)-2-methylpropyl]-2,3dihydro-1*H*-benzo[*f*]isoindol-1-one (30a)

Using **28** (5.00 g, 7.3 mmol) as the starting material and the same procedure as described for the synthesis of **27a**, **30a** (1.46 g, 64%) was obtained as a colorless power. The analytical sample was obtained by recrystallization from EtOH as a colorless powder. Mp 204.0–208.0 °C. ¹H NMR (CDCl₃ + CD₃OD) δ : 0.80 (3H, d, *J* = 7.0 Hz), 1.02 (3H, d, *J* = 7.0 Hz), 2.76 (1H, septet, *J* = 7.0 Hz), 4.56 (2H, s), 7.03 (1H, d, *J* = 1.2 Hz), 7.53 (1H, d, *J* = 1.2 Hz), 7.65 (1H, dd, *J* = 8.4, 1.6 Hz), 7.90–7.96 (2H, m), 8.13 (1H, s), 8.31 (1H, s). IR (KBr): 3208, 1671 cm⁻¹. LCMS (API): *m/z* 322.1 [M+H]⁺. Anal. Calcd for C₁₉H₁₉N₃O₂·C₂H₅OH: C, 68.64; H, 6.86; N, 11.44. Found: C, 68.30; H, 6.84; N, 11.29.

5.61. 6-[1-Hydroxy-1-(1*H*-imidazol-4-yl)-2-methylpropyl]-2methyl-2,3-dihydro-1*H*-benzo[*f*]isoindol-1-one (30b)

Using **28** (0.99 g, 1.5 mmol) as the starting material and the same procedure as described for the synthesis of **27a**, **30b** (0.11 g, 22%) was obtained as a colorless power. The analytical sample was obtained by recrystallization from EtOH (colorless powder). Mp 260 °C decomp. ¹H NMR (CDCl₃ + CD₃OD) δ : 0.81 (3H, d, *J* = 6.6 Hz), 1.02 (3H, d, *J* = 6.6 Hz), 2.70–2.90 (1H, m), 3.27 (3H, s), 4.59 (2H, s), 7.04 (1H, s), 7.54 (1H, s), 7.65–7.73 (1H, m), 7.92–7.96 (2H, m), 8.14 (1H, s), 8.27 (1H, s). ¹³C NMR (DMSO-*d*₆) δ : 16.7, 17.4, 29.1, 36.6, 51.1, 77.4, 112.0, 121.8, 121.9, 123.4, 125.5, 128.0, 130.0, 130.8, 134.1, 134.1, 134.2, 136.5, 147.2, 147.4, 167.1. IR (KBr): 3167, 1663, 1400, 1150, 810, 625 cm⁻¹. LCMS (API): *m/z* 336.2 [M+H]⁺. Anal. Calcd for C₂₀H₂₁N₃O₂: C, 71.62; H, 6.31; N, 12.53. Found: C, 71.22; H, 6.61; N, 12.46.

5.62. Optical resolution of 27a

Optical resolution of **27a** (13.1 g) was performed using preparative HPLC on a Chiralpak AD column (50 mmID \times 500 mmL, eluent: hexane/EtOH/diethylamine = 85:15:0.1, flow rate: 80–100 mL/min, temperature: 35 °C) to yield (–)-**27a** (5.27 g, 99.9% enantiomeric excess [ee]) as a colorless powder and (+)-**27a** (5.39 g, 99.7% ee) as colorless amorphous solid. (–)-**27a**: Mp 220.0–222.0 °C. ¹H NMR (DMSO-*d*₆) δ : 0.66 (3H, d, *J* = 6.8 Hz), 0.75–0.97 (3H, m), 2.67–2.86 (1H, m), 4.71 (2H, s), 5.18 (1H, br s), 7.02 (1H, br s), 7.56 (1H, br s), 7.64 (1H, d, *J* = 8.3 Hz), 7.82–8.10 (3H, m), 8.25 (1H, br s), 8.58 (1H, s), 11.82 (1H, br s). IR (KBr): 3185, 2976, 1686 cm⁻¹. LCMS (API): *m/z* 322.1 [M+H]⁺. Anal. Calcd for C₁₉H₁₉N₃O₂·0.5H₂O: C, 69.07; H, 6.10; N, 12.72. Found: C, 69.37; H, 6.11; N, 12.68. $[\alpha]_D^{20} = -41.2$ (*c* 0.9520, MeOH). (+)-27a: The spectral data of (+)-27a were identical to those of the (–)-27a except for elemental analysis and optical rotation. LCMS (API): *m/z* 322.1 [M+H]⁺. Anal. Calcd for C₁₉H₁₉N₃O₂·1.25H₂O·0.25AcOEt: C, 65.65; H, 6.47; N, 11.48. Found: C, 65.40; H, 6.68; N, 11.36. $[\alpha]_D^{20} = +35.4$ (*c* 1.0085, MeOH).

5.63. Optical resolution of 27b

Optical resolution of 27b (2.40 g) was performed using preparative HPLC on a Chiralpak AD column (50 mmID \times 500 mmL eluent: hexane/EtOH = 40:60, flow rate: 60 mL/min, temperature: rt) to yield (-)-27b (1.10 g, 99.9% ee) as a colorless powder and (+)-27b (1.00 g, 99.8% ee) as a colorless powder. (-)-27b: Mp 207.0-209.0 °C. ¹H NMR (DMSO- d_6) δ : 0.65 (3H, d, I = 6.6 Hz), 0.83 (3H, d, *I* = 6.6 Hz), 2.65–2.87 (1H, m), 3.14 (3H, s), 4.78 (2H, s), 5.17 (1H, s), 7.04 (1H, s), 7.42-7.76 (2H, m), 7.80-8.08 (3H, m), 8.26 (1H, s), 11.83 (1H, br s). The ¹³C NMR spectral data of (-)-27b was identical to those of the **27b**. IR (KBr): 3148, 2971, 1669 cm⁻¹. LCMS (API): *m*/*z* 336.2 $[M+H]^+$. Anal. Calcd for $C_{20}H_{21}N_3O_2 \cdot 0.75H_2O$: C, 68.85; H, 6.50; N, 12.04. Found: C, 68.71; H, 6.38; N, 11.99. $[\alpha]_{D}^{20} = -33.4$ (*c* 0.226, MeOH). (+)-27b: The spectral data of (+)-27b were identical to those of the (-)-27b except for elemental analysis and optical rotation. Mp 207.0-209.0 °C. LCMS (API): m/z 336.1 [M+H]⁺. Anal. Calcd for C₂₀H₂₁N₃O₂·0.75H₂O: C, 68.85; H, 6.50; N, 12.04. Found: C, 68.99; H, 6.45; N, 11.95. $[\alpha]_{D}^{20} = +34.5$ (*c* 0.258, MeOH).

5.64. 7-[(1*R*)-1-{1-[(4-Bromophenyl)sulfonyl]-1*H*-imidazol-4-yl}-1-hydroxy-2-methylpropyl]-2-methyl-1,2-dihydro-3*H*-benzo[*e*]-isoindol-3-one (31)

4-Bromobenzenesulfonyl chloride (460 mg, 1.8 mmol) was added to a solution of **(+)-27b** (503 mg, 1.5 mmol) in DMF (12 mL) and the mixture was stirred at rt for 3 h. The mixture was poured into water and the aqueous phase extracted with AcOEt. The combined organic layer was washed with 10% citric acid solution, H₂O and brine, dried over MgSO₄ and evaporated. The residue was crystallized from AcOEt–*i*-Pr₂O to give **31** (730 mg, 88%). Analytical sample was obtained by recrystallization from THF–MeOH. Mp 170 °C. IR (KBr): 3345, 1671, 745, 635 cm⁻¹. ¹H NMR (CDCl3) δ : 0.76 (3H, d, *J* = 6.6 Hz), 0.91 (3H, d, *J* = 6.6 Hz), 2.79 (1H, septet, *J* = 6.6 Hz), 2.96 (1H, s), 3.27 (3H, s), 4.66 (2H, s), 7.31 (1H, d, *J* = 1.4 Hz), 7.64–7.88 (8H, m), 7.94 (1H, d, *J* = 1.4 Hz), 8.14 (1H, s). Anal. Calcd for C₂₆H₂₄BrN₃O₄S·MeOH: C, 55.29; H, 4.81; N, 7.13. Found: C, 55.48; H, 4.75; N, 6.98.

5.65. 6-Bromo-N,N-diisopropyl-2-naphthamide (32b)

A solution of 6-bromo-2-naphthoic acid **32a** (100 g, 398 mmol), thionylchloride (37.7 mL, 517 mmol) and DMF (0.5 mL) in THF (1000 mL) was stirred at 60 °C for 90 min. After cooling to rt, the solvent and excess amount of thionylchloride was evaporated. The resulting residue was dissolved in dry THF (400 mL) and the solution was added dropwise to a cooled (0 °C) solution of diisopropylamine (112 mL, 799 mmol) and triethylamine (112 mL, 804 mmol) in THF (800 mL). After being stirred at rt for 1 h, about 50% of the solvent was evaporated. Then the mixture was diluted with AcOEt and the organic phase was washed with H₂O, 1 N NaOH solution and brine, dried over MgSO₄ and evaporated. The residue was washed with *i*-Pr₂O to give **32b** (117 g, 88%) as a colorless

crystal. ¹H NMR (CDCl₃) δ : 1.36 (12H, br s), 3.71 (2H, br s), 7.44 (1H, dd, *J* = 1.2 Hz, 8.6 Hz), 7.58 (1H, dd, *J* = 2.2 Hz, 8.8 Hz), 7.70–7.79 (3H, m), 8.01 (1H, d, *J* = 1.2 Hz). IR (KBr): 2968, 1620, 1435, 1369, 1333, 895, 814 cm⁻¹. LCMS (API): *m/z* 334.1 [M+H]⁺. Anal. Calcd for C₁₇H₂₀NOBr: C, 61.09; H, 6.03; N, 4.19; Br, 23.91. Found: C, 61.22; H, 6.08; N, 4.12.

5.66. 6-[(2*R*)-2-(*tert*-Butyldimethylsilyloxy)propanoyl]-*N*,*N*-diisopropyl-2-naphthamide (34a)

Solution **32b** (46.80 g, 140.0 mmol) in THF (400 mL) was added dropwise to a cooled (-70 °C) solution of *n*-BuLi (1.6 mol/L in hexane; 96.3 mL, 154 mmol) in toluene (900 mL) and the mixture was stirred at -70 °C for 30 min. A solution of **33** (34.45 g, 126.0 mmol) in toluene (50 mL) was added to the mixture and the solution was stirred at -78 °C for 30 min. The reaction was quenched with aq NH₄Cl and the mixture was warmed to rt. After extraction with AcOEt, the combined organic layers were dried over MgSO₄ and evaporated to give **34a** as a pale yellow oil. This compound was directly used without further purification in the next step. ¹H NMR (CDCl₃) δ : 0.06 (3H, s), 0.12 (3H, s), 0.91 (9H, s), 1.10–1.60 (12H, m), 1.60 (3H, d, J = 7.0 Hz), 3.50–4.00 (2H, br m), 5.04 (1H, q, J = 7.0 Hz), 7.50 (1H, dd, J = 8.4 Hz), 7.83 (1H, s), 7.91 (1H, d, J = 8.4 Hz), 8.14 (1H, d, J = 8.4, 1.4 Hz), 8.72 (1H, s). IR (KBr): 1694, 1630, 1441, 1335, 835 cm⁻¹.

5.67. 6-[(2R)-2-Hydroxypropanoyl]-N,N-diisopropyl-2-naphthamide (34b)

TBAF (41.01 g, 157 mmol) was added to a cooled ($-10 \,^{\circ}$ C) solution of **34a** (25.7 g, 74.9 mmol) in THF (900 mL) and the mixture was stirred at 0 $^{\circ}$ C for 1 h. The mixture was diluted with brine and the aqueous phase was extracted with AcOEt. The combined organic layers were washed with brine and dried over MgSO₄. After removal of the solvent in vacuo, the residue was chromatographed on silica gel (hexane/AcOEt = 2:1–2:3) and washed with diethylether to give **34b** (24.00 g, 58% from **33**) as a colorless solid. Mp 174 $^{\circ}$ C. [α]_D²⁰ = +38.2 (*c* 0.726, MeOH). ¹H NMR (CDCl₃) δ : 1.10–1.70 (12H, br m), 1.52 (3H, d, *J* = 6.9 Hz), 3.40–3.90 (2H, br), 3.84 (1H, d, *J* = 6.9 Hz), 5.32 (1H, quint, *J* = 6.9 Hz), 7.52 (1H, dd, *J* = 8.4, 1.8 Hz), 7.84 (1H, s), 7.95 (1H, d, *J* = 8.4 Hz), 8.00–8.04 (2H, m), 8.45 (1H, s). IR (KBr): 3493, 1678, 1628, 1117, 826 cm⁻¹. LCMS (API): *m/z* 328.1 [M+H]⁺. Anal. Calcd for C₂₀H₂₅NO₃: C, 73.37; H, 7.70; N, 4.28. Found: C, 73.24; H, 7.60; N, 4.21.

5.68. 6-[(15,2R)-1,2-Dihydroxy-1-isopropylpropyl]-*N*,*N*-diisopropyl-2-naphthamide (35)

A solution of *i*-propylmagnesium bromide (0.7 M in THF; 500 mL, 350 mmol) was added dropwise over 2 h to a cooled (-10 °C) solution of **34b** (20.08 g, 61.3 mmol) in THF (300 mL) and the mixture was stirred at 0 °C for 1 h. The reaction was quenched with satd aq NH₄Cl and the aqueous layer was extracted with AcOEt. The combined organic layers were dried over MgSO₄ and concentrated in vacuo. The residue was crystallized from i- Pr_2O to give **35** (12.35 g, 54%) as a colorless solid. The purity of the obtained **35** was >95% as determined by HPLC using a Chiralpak AD column. The analytical sample was obtained by recrystallization from AcOEt. Mp 200 °C. $[\alpha]_D^{20} = +19.9$ (*c* 0.545, MeOH). ¹H NMR (CDCl₃) δ : 0.87 (3H, d, *J* = 6.6 Hz), 0.95 (3H, d, *J* = 6.6 Hz), 1.06 (3H, d, J = 6.6 Hz), 1.00–1.70 (12H, br m), 1.65 (1H, d, J = 4.2 Hz), 2.45 (1H, septet, J = 6.6 Hz), 2.61 (1H, s), 3.50–4.00 (2H, br), 4.37 (1H, dq, *J* = 4.2, 6.6 Hz), 7.41 (1H, dd, *J* = 8.4, 1.8 Hz), 7.48 (1H, dd, J = 8.4, 1.8 Hz), 7.77-7.90 (4H, m). IR (KBr): 3511, 2971, 1617, 1443, 1372, 1341 cm⁻¹. LCMS (API): *m/z* 372.2

 $[M+H]^+$. Anal. Calcd for $C_{23}H_{33}NO_3$: C, 74.36; H, 8.95; N, 3.77. Found: C, 74.39; H, 8.77; N, 3.73.

5.69. 7-[(1*S*,2*R*)-1,2-Dihydroxy-1-isopropylpropyl]-2-methyl-1,2-dihydro-3*H*-benzo[*e*]isoindol-3-one (38a)

n-BuLi (1.6 mol/L, 103.8 mL, 166 mmol) was added dropwise to a cooled (-70 °C) solution of 35 (12.35 g, 33.2 mmol) and tetramethylethylenediamine (TMEDA) (60 mL) in THF (250 mL) and the mixture was stirred at -70 °C for 2.5 h. To the mixture, DMF (25 mL) was added dropwise, and the reaction mixture was further stirred at -70 °C for 1 h. After diluting with aq NH₄Cl solution, the aqueous layer was extracted with AcOEt. The combined organic layers were washed with H₂O and brine, dried over MgSO₄. Removal of the solvent in vacuo gave a crude product of 36a and **36b** (**36a**:**36b** = ca. 6:1) as amorphous solid. The crude product of 36a and 36b was dissolved in CH₂Cl₂ (250 mL) and methylamine (2 M in THF, 67.5 mL, 135 mmol) was added. After adjusting the pH of the reaction mixture to 6-7 with acetic acid (ca. 9 mL), NaB-H(OAc)₃ (59.3 g, 280 mmol) was added dropwise to the reaction mixture, which was then stirred at rt for 62 h. After being diluted with 2 N HCl, the aqueous layer was washed with AcOEt. The aqueous layer was then made alkaline with 10 N NaOH solution and extracted with AcOEt. The combined organic layers were dried over MgSO₄ and evaporated in vacuo to give a crude product of **37a** and 37b.

n-BuLi (1.6 M in hexane; 104 ml, 166 mmol) was added dropwise to a cooled (-60 °C) solution of diisopropylamine (24.5 mL, 175 mmol) in THF (250 mL) and the mixture was stirred at -70 °C for 10 min to prepare the LDA solution. A solution of the crude product of 37a and 37b in THF (70 mL) was then added dropwise, and the reaction mixture was allowed to warm to 0 °C over 2 h. After being diluted with aq NH₄Cl solution, the aqueous layer was extracted with AcOEt. The combined organic layers were dried over MgSO₄ and evaporated. The residue was purified by column chromatography on silica gel (AcOEt) and crystallized from THF-AcOEt to yield a mixture of **38a** and **38b** (4.33 g, 42%, **38a:38b** = 93:7) as a colorless solid. The ratio of the obtained **38a** and **38b** was determined by HPLC using Chiralpak AD column. ¹H NMR (CDCl₃) δ : 0.89 (3H, d, I = 6.9 Hz), 0.95 (3H, d, I = 6.9 Hz), 1.07 (3H, d, *J* = 6.3 Hz), 1.82 (1H, d, *J* = 6.3 Hz), 2.46 (1H, septet, *I* = 6.9 Hz), 2.69 (1H, s), 3.29 (3H, s), 4.41 (1H, quint, *I* = 6.3 Hz), 4.70 (2H, s), 7.61 (1H, dd, J = 8.7, 1.8 Hz), 7.80-7.97 (3H, m), 8.01 (1H, d, I = 1.8 Hz). IR (KBr): 3420, 1686, 826, 747 cm⁻¹. LCMS (API): m/z 314.2 [M+H]⁺. Anal. Calcd for C₁₉H₂₃NO₃·0.1AcOEt: C, 72.32; H, 7.45; N, 4.35. Found: C, 72.37; H, 7.61; N, 4.32.

5.70. 7-[(1S)-1-Acetyl-1-hydroxy-2-methylpropyl]-2-methyl-1,2-dihydro-3*H*-benzo[*e*]isoindol-3-one (39)

Dimethyl sulfoxide (DMSO) (3.63 mL, 51.1 mmol) was added dropwise to a cooled (-70 °C) solution of oxalylchloride (2.22 mL, 25.5 mmol) in CH₂Cl₂ (40 mL) and the mixture was stirred at -70 °C for 1 h. A solution of 38a (4.00 g, 12.8 mmol, 38a:38b = 93:7) in CH₂Cl₂/DMSO (1:1, 12 mL) was added dropwise, and the reaction mixture was warmed to $-20\,^{\circ}\text{C}$ over 1 h. After cooling to -70 °C, triethylamine (10.7 mL, 76.6 mmol) was added dropwise to the mixture and the solution was allowed to warm to rt and stirred for a further 2 h. The resulting mixture was diluted with H₂O and the combined organic layers were washed with H₂O and dried over MgSO₄. After removal of the solvent in vacuo, the resulting solid was washed with i-Pr₂O and recrystallized from AcOEt to give 39 (3.10 g, 33% from 35) as a colorless solid. The purity of the obtained 39 was >99% as determined by HPLC using a Chiralpak AD column. Mp 171 °C. $[\alpha]_{D}^{20} = -22.9$ (*c* 0.615, MeOH). ¹H NMR (CDCl₃) δ : 0.94 (3H, d, J = 6.9 Hz), 0.96 (3H, d, J = 6.9 Hz), 2.20 (3H, s), 2.97 (1H, septet, J = 6.9 Hz), 3.29 (3H, s), 4.63 (1H, s), 4.70 (2H, s), 7.77 (1H, dd, J = 8.7, 1.8 Hz), 7.84–7.92 (3H, m), 8.17 (1H, d, J = 1.8 Hz). IR (KBr): 3335, 1705, 1667, 1171, 748 cm⁻¹. LCMS (API): m/z 312.2 [M+H]⁺. Anal. Calcd for C₁₉H₂₁NO₃·0.6AcOEt: C, 70.57; H, 7.14; N, 3.85. Found: C, 70.60; H, 7.16; N, 4.12.

5.71. 7-[(1S)-3-Bromo-1-hydroxy-1-isopropyl-2-oxopropyl]-2methyl-1,2-dihydro-3*H*-benzo[*e*]isoindol-3-one (40)

Pyridinium bromide perbromide (3.17 g, 9.9 mmol) was added to a cooled (0 °C) solution of **39** (2.80 g, 9.0 mmol) in THF (35 mL) and the mixture was stirred at rt for 66 h. The reaction mixture was diluted with aqueous sodium thiosulfate solution and the aqueous phase was extracted with AcOEt. The combined organic layers were washed with 10% aq citric acid solution and aq NaHCO₃ solution, and dried over MgSO₄. After removal of the solvent in vacuo, the residue was chromatographed on silica gel (hexane/AcOEt = 1:1–1:2) to give **40** (2.97 g, 85%) including starting material **39** as a colorless solid. This compound was used without further purification in the next step. ¹H NMR (CDCl₃) δ : 0.80 (3H, d, *J* = 6.6 Hz), 1.04 (3H, d, *J* = 6.6 Hz), 2.99 (1H, septet, *J* = 6.6 Hz), 3.28 (3H, s), 3.97 (1H, s), 4.27 (1H, d, *J* = 15.0 Hz), 4.34 (1H, d, *J* = 15.0 Hz), 4.68 (2H, s), 7.72–7.91 (4H, m), 8.19 (1H, d, *J* = 1.4 Hz). IR (KBr): 1670 cm⁻¹.

5.72. 7-{(15,2Z)-3-Bromo-1-isopropyl-1,2-bis[(trimethylsilyl)oxy]prop-2-enyl}-2-methyl-1,2-dihydro-3*H*-benzo[*e*]isoindol-3-one (41)

TBAF (1 M solution in THF, 32 mL, 0.032 mmol) was added to a solution of **40** (0.63 g, 1.6 mmol) and *N*,O-bis(trimethylsilyl)acetamide (2.4 mL, 9.7 mmol) in DMF (8 mL) and the reaction mixture was stirred at rt for 16 h. After being diluted with AcOEt, the mixture was washed with H₂O, followed by brine, before drying over MgSO₄. After removal of the solvent in vacuo, the residue was chromatographed on silica gel (hexane/AcOEt = 13:7–7:13) to give **41** (0.55 g, 54% from **39**) as colorless amorphous solid. ¹H NMR (CDCl₃) δ : -0.14 (9H, s), 0.09 (9H, s), 0.85 (3H, d, *J* = 6.9 Hz), 1.00 (3H, d, *J* = 6.9 Hz), 2.59 (1H, septet, *J* = 6.9 Hz), 3.31 (3H, s), 4.72 (2H, s), 5.90 (1H, s), 7.64 (1H, dd, *J* = 9.0, 4.8 Hz), 7.78–7.94 (4H, m). IR (KBr): 1690, 1252, 843 cm⁻¹. LRMS (FAB): *m/z* 534 [M+H]⁺.

5.73. 7-[(1S)-1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-methyl-1,2-dihydro-3H-benzo[e]isoindol-3-one [(-)-27b]

Saturated ammonia solution in MeOH (1.5 mL) and formamidine acetate (31 mg, 0.3 mmol) was added to a cooled (-15 °C) solution of **41** (160 mg, 0.30 mmol) in THF (0.5 mL) and the resulting mixture was stirred at -15 °C for 30 min. The reaction mixture was allowed to warm to rt over 3 h and stirred at rt for a further 90 h. After removing excess NH₃ and MeOH, the residue was diluted with brine. The aqueous layer was extracted with AcOEt/ THF (1:1) and the combined organic layer was dried over MgSO₄. After removal of the solvent in vacuo, the residue was chromatographed on silica gel (CH₂Cl₂/MeOH = 30:1–6:1) to give (-)-**27b** (54 mg, 54%). The optical purity of the obtained (-)-**27b** was >99% ee as determined by HPLC using a Chiralpak AD column.

5.74. Homology modeling

Homology models of 17,20-lyase (CYP17) were constructed based on the crystal structure of mammalian CYP2C5 (PDB code:1DT6) using the Insight II homology module (v2000, Accelrys Inc.). Using the Search/Generate-Loops function of Insight II, conformations of the insertions and deletions in the alignment were obtained with reference to the known 3-D structures. After some manual adjustments to remove large steric hindrances, the structure was subjected to 1000 steps of energy minimization with the steepest descent minimizer, followed by 5000 steps with the conjugate gradient minimizer, to a maximum gradient of 0.1 kcal/mol⁻¹ Å⁻¹, using the Discover-ESFF force field (v980, Accelrys Inc.). During the minimization procedure, the dielectric constant was set to 4 * r, where r is the distance between two interacting atoms, and the force constant of tethering constraints for the backbone of structurally conserved regions and heme was set to $40 \text{ kcal/}Å^2$ to prevent a large movement from the initial positions.

5.75. Docking of inhibitors

Covalent bonding models of imidazole were constructed by full energy minimization using the Discover-ESFF force field. The residual parts of compounds were connected to the imidazole. Using the Search—Compare module of Insight II, the stable binding mode of each compound was investigated by systematic bond rotation within the ligand, including of some side chains around the ligand. Energy minimization was continued using the Discover-ESFF force field. The energy minimization conditions were the same as those used for the homology modeling.

5.76. X-ray crystallographic analysis of compound 31

A single crystal $(0.40 \times 0.40 \times 0.16 \text{ mm})$ of **31** was obtained by recrystallization from THF/MeOH. Reflection data were collected using a Rigaku AFC5R diffractometer with graphite monochromated Cu K α radiation. The structure was determined by direct methods (SIR92), and refined using the full-matrix least-squares techniques (SHELXL-97) with anisotropic temperature factors for the non-hydrogen atoms. Hydrogen atoms were included using a riding model. The crystal contained two host (31) molecules and two methanol molecules in the asymmetric unit. The absolute configuration was determined by the Flack parameter of -0.03 (3). Crystal data: $C_{26}H_{24}BrN_{3}O_{4}S\cdot CH_{3}OH$; *M* = 586.50; monoclinic; space group *P*2₁ (#4): cell constants a = 14.684(2) Å. b = 10.318(1) Å. c =18.927(2) Å, $\beta = 112.256(7)^\circ$, V = 2653.9(5) Å³; Z = 4; Dc = 1.468 g/ cm³; unique reflections, 9180; observed reflections $[I > 2\sigma(I)]$, 5158; $R_1 = 0.072$, $wR_2 = 0.241$. Further details of the X-ray structure data are available on request from the Cambridge Crystallographic Data Centre (deposition number CCDC 781827).

5.77. Inhibition of rat 17,20-lyase in vitro

Inhibitory activity against rat enzymes was determined according to a previously described method⁵⁸ with some modifications. Testes excised from 13-week-old male Sprague-Dawley (SD) rats were homogenized and testicular microsomes were prepared by centrifugation. The reaction mixture consisted of 75 mM phosphate buffer (pH 7.4), 7 µg the microsome protein, 10 nM $[1,2-^{3}H]-17\alpha$ -hydroxyprogesterone (NEN), 5 mM NADPH (Oriental Yeast), and 1–1000 nM test compound in a total volume of 20 μ L. The concentration of reagents was expressed as the final concentration in the reaction mixture. The test compounds were serially diluted with dimethylformamide, and then diluted fivefold with distilled water before 5 µL samples were added to the reaction mixture. The reaction was terminated with the addition of 40 μ L of ethyl acetate after 15 min (17,20-lyase) incubation at 37 °C, followed by vortexing for 30 s and a brief centrifugation. Samples $(30 \,\mu\text{L})$ of the organic phase were applied to silica gel TLC plates (Whatman, LHPK). The substrate and products, androstenedione and testosterone, were separated using the toluene-acetone (7:2) solvent system. Detection of the spots and measurement of the radioactivity as PSL were performed using a BAS2000 Bio-image

analyzer (FUJIX). The concentrations of the test compounds required to reduce the concentration of the products by 50% (IC_{50}) were calculated.

5.78. Inhibition of human 17,20-lyase in vitro

Inhibition of human enzymes was determined as above. The reaction mixture consisted of 75 mM phosphate buffer (pH 7.4), 1 mM magnesium chloride, 0.5 pmol recombinant P450c17 (Biotechnology Laboratories, Takeda), 0.5 pmol recombinant cytochrome b5 (Pan Vera), 20.8 ng recombinant NADPH-cytochrome P450 reductase (Pan Vera), 10 nM [1,2-³H]-17α-hydroxypregnenolone (Amersham), 5 mM NADPH (Oriental Yeast), and 1-1000 nM test compound in a total volume of 20 µL. The test compounds were serially diluted with dimethylformamide, and then diluted fivefold with distilled water before 5 μ L of the solution was added to the reaction mixture. The reaction was terminated by the addition of 40 uL of ethyl acetate after 15 min (17.20-lyase) incubation at 37 °C, then vortexing for 30 s and briefly centrifuging. Organic phases $(30 \text{ }\mu\text{L})$ were applied to silica gel thin layer chromatography plates (Whatman, LHPK). The substrate and product DHEA were separated using the cyclohexane-ethyl acetate (3:2) solvent system.

5.79. Screening for the inhibition of CYP3A4 in vitro (Tables 1-4)

The reaction mixture consisted of 50 mM phosphate buffer (pH 7.4), 10 pmol/mL recombinant CYP3A4 (Gentest), 100 μ M testosterone, NADPH regenerating system (0.5 mM NADP; Oriental Yeast), 5 mM glucose-6-phosphate (Oriental Yeast), 1 mM MgCl₂, 1.5 unit/mL G-6-P dehydrogenase (Oriental Yeast)), and 1 or 10 μ M test compound in a total volume of 200 μ L. The total microsome protein content was adjusted by control microsome protein (Gentest). The concentration of reagents was expressed as the final concentration in the reaction mixture. The reaction mixture was incubated for 30 min at 37 °C and terminated by adding 200 μ L acetonitrile. After adding 400 μ L water, the reaction mixture was centrifuged at 14,000 rpm for 10 min. The 6-hydroxytestosterone content in the supernatant was determined by HPLC analysis (Shimadzu LC-10, column: Inertsil ODS-3 (4.6 × 150 mm) (GL Sciences)).

5.80. Inhibition of rat 11-hydroxylase in vitro

Adrenal glands excised from SD rats were homogenized, and the mitochondrial fraction was prepared through a series of centrifugation steps. Rat 11-hydroxylase activity was measured according to the method described for side-chain cleavage activity by Uzgiris et al.⁵⁹ with some modifications. The reaction mixture contained 200 mM mannitol, 4.5 mM HEPES, 2.3 mM potassium phosphate (pH 7.4), 0.1 mM EDTA-2 K, 0.03% BSA (crystallized, Miles), 4.5 mM NADPH (Oriental Yeast), 11 mM calcium chloride, 4 µg mitochondria protein, 10 nM [1,2-³H]-hydroxy-11-deoxycorticosterone (11-deoxycortisol) (NEN, dissolved in 0.02% Tween-80), and 1-1000 nM test compound in a total volume of 150 µL. The test compounds were serially diluted with dimethylformamide, and 1.5 µL samples were directly added to the reaction mixture. The concentration of reagents was expressed as the final concentration in the reaction mixture. The reaction was terminated by the addition of 400 μ L ethyl acetate and 100 μ L distilled water after 30 min incubation at 37 °C, followed by vortexing for 30 s and a brief centrifugation. Organic phase (300 µL) was transferred to a new tube, and evaporated until dry with nitrogen gas. The steroids were dissolved with 30 µL ethyl acetate. The whole volume was applied to silica gel TLC plates (Whatman, LHPK). The substrate and the products, 11-deoxycortisol and cortisol, were separated using the toluene–acetone (7:2) solvent system.

5.81. Effect of (-)-27b on metabolic activities of CYP-expressing microsomes (Table 5)

The effect of (-)-27b on CYP isoforms was assessed by incubating a marker substrate with the microsomes expressing each human CYP isoform in the presence of 3, 10, and 30 µmol/L of (-)-27b. The incubation mixture contained 10 mmol/L MgCl₂, 3.2 mg/mL glucose-6-phosphate, 0.8 mg/mL β-NADP+ and 4 units/mL glucose-6-phosphate dehydrogenase in 80 mmol/L phosphate buffer (pH 7.4). In the case of 2C9, 80 mmol/L Tris-HCl buffer (pH 7.4) was used instead of phosphate buffer. After preincubation of (-)-27b and CYP isoform-specific substrate in the mixture at 37 °C for 5 min, the reaction was initiated by the addition of microsomes derived from specific CYP-expressing human B-lymphoblastoid cells. The concentration of the substrates was referenced from the data sheet from GENTEST Corp. [(±)-bufuralol 1'-hydroxylation for CYP2D6 and testosterone 6β-hydroxylation activity for CYP3A4] or published reports (tolbutamide hydroxylation for CYP2C8 and 2C9)^{60,61} with slight modifications.

The marker reactions specific for CYP isoforms except for CYP3A4, were measured by published analytical methods^{60,62–66} with slight modifications. Testosterone 6 β -hydroxylation activity for CYP3A4 was analyzed under the following HPLC conditions: Inertsil ODS-2 column (150 × 4.6 mm I.D.; GL Science, Tokyo, Japan), detection wavelength 254 nm, flow rate 1.0 mL/min, column temperature 50 °C, and mobile phase 10 mmol/L acetate buffer (pH4.3)/acetonitrile = 7/3. Control marker enzymatic activities were measured for the preincubation samples in the presence of methanol alone without (–)-**27b**.

5.82. Effects of (–)-27b on serum testosterone and DHEA concentrations in male cynomolgus monkeys

Adult male cynomolgus monkeys housed in a temperaturecontrolled room $(23 \pm 2 \,^{\circ}C)$ with a 12:12 h light/dark cycle (illumination from 7:00 am to 7:00 pm) were used for the single dosing experiments. All procedures were performed according to protocols approved by the Institutional Animal Care and Use Committee of Pharmaceutical Research Division, Takeda. The test compound (-)-**27b** was suspended in 0.5% methylcellulose and orally administered at a dose of 1 mg/kg. Blood samples were collected just before dosing, and 4 and 8 h after the dosing. Serum was stored at $-30 \,^{\circ}C$ until assayed by radioimmunoassay (RIA). Concentrations of testosterone were determined using a Testosterone I-125 kit (Dia Sorin s.r.l., Italy), according to the manufacturer's directions.

5.83. Pharmacokinetic studies

Compound (–)-27b was administered to non-fasted Crl:CD(SD)IGS rats (male, 8 weeks old, n = 3) intravenously at a dose of 1 mg/kg and orally at a dose of 10 mg/kg. Blood samples were collected at 5, 10, 15, and 30 min and 1, 2, 4, 8, 24 h after intravenous administration, or at 15 and 30 min and 1, 2, 4, 8, 24 h after obtain the plasma fraction. The blood samples were centrifuged to obtain the plasma fraction. The plasma samples were deproteinized with acetonitrile. After centrifugation, the supernatant was dried under N₂. The residue was reused with HPLC mobile phase (A:B = 90:10) and analyzed by HPLC. The analytical conditions using HPLC were: column, L-column ODS (4.6 mm × 250 mm); mobile phase, (A) 0.01 mol/L ammonium acetate:(B) acetonitrile = 78:22; flow rate, 1.0 mL/min; column temperature, 40 °C.

Acknowledgments

The authors thank Dr. S. Furuya for helpful discussions throughout this work, Ms. K. Higashikawa for single-crystal X-ray analysis, Mr. A. Furuta for pharmacokinetic studies, Ms. H. Shinohara and Mr. T. Masaki for technical support and Dr. F. W. Dahlquist (University of Oregon) for kindly providing vector pCWori. This work was funded by Millennium Pharmaceuticals, Inc. The authors would also like to acknowledge FireKite for editorial assistance in the development of this manuscript, which was supported by funding from Millennium Pharmaceuticals, Inc.

References and notes

- Greenlee, R. T.; Murray, T.; Hill-Harmon, M. B.; Thun, M. J. CA Cancer J. Clin. 2001, 51, 15.
- Kozlowski, J. M.; Grayhack, J. T. Carcinoma of the Prostate. In Adult and Pediatric Urology; Gillen-water, J. J., Grayhack, J. T., Howards, S. S., Duckett, J. W., Eds.; Mobsby Year Book: St. Louis, MO, 1991. Chapter 34.
- 3. McConnell, J. D. Urol. Clin. North Am. 1991, 18, 1.
- 4. Hellerstedt, B. A.; Pienta, K. J. CA Cancer J. Clin. 2002, 52, 154.
- 5. Yamaoka, M.; Hara, T.; Kusaka, M. Clin. Cancer Res. 2010, 16, 4319.
- 6. Nelson, W. G.; De Marzo, A. M.; Isaacs, W. B. N. Eng. J. Med. 2003, 349, 366.
- 7. Miller, W. L. Endocr. Rev. 1988, 9, 295.
- De Coster, R.; Wouters, W.; Bruynseels, J. J. Steroid Biochem. Mol. Biol. 1996, 56, 133.
- Locke, J. A.; Fazli, L.; Adomat, H.; Smyl, J.; Weins, K.; Lubik, A. A.; Hales, D. B.; Nelson, C. C.; Gleave, M. E.; Tomlinson Guns, E. S. Prostate 2009, 69, 928.
- 10. Van den Bossche, H. J. Steroid Biochem. Mol. Biol. 1992, 43, 1003.
- 11. Potter, G. A.; Barrie, S. E.; Jarman, M.; Rowlands, M. G. J. Med. Chem. 1995, 38, 2463.
- 12. Li, J.; Li, Y.; Son, C.; Brodie, A. J. Med. Chem. 1996, 39, 4335.
- 13. Njar, V. C. O.; Hector, M.; Hartmann, R. W. Bioorg. Med. Chem. 1996, 4, 1447.
- 14. Ling, Y.; Li, J.; Liu, Y.; Kato, K.; Klus, G. T.; Brodie, A. M. H. J. Med. Chem. **1997**, 40, 3297.
- Ling, Y.; Li, J.; Kato, K.; Liu, Y.; Wang, X.; Klus, G. T.; Marat, K.; Nnane, I. P.; Brodie, A. M. H. Bioorg. Med. Chem. 1998, 6, 1683.
- Njar, V. C. O.; Kato, K.; Nnane, I. P.; Grigoryev, D. N.; Long, B. J.; Brodie, A. M. H. J. Med. Chem. 1998, 41, 902.
- 17. Jarman, M.; Smith, J. H.; Nicholls, P. J.; Simons, C. Nat. Prod. Rep. **1998**, 24, 495.
- 18. Njar, V. C. O.; Brodie, A. M. H. Curr. Pharm. Des. 1999, 5, 163.
- McCague, R.; Rowlands, M. G.; Barrie, S. E.; Houghton, J. J. Med. Chem. 1990, 33, 3050.
- 20. Sergejew, T.; Hartmann, R. W. J. Enzyme Inhib. 1994, 8, 113.
- Ahmed, S.; Smith, J. H.; Nicholls, P. J.; Whomsley, R.; Cariuk, P. Drug Des. Discuss. 1995, 13, 27.
- Rowlands, M. G.; Barrie, S. E.; Chan, F.; Jarman, M.; McCague, R.; Potter, G. A. J. Med. Chem. 1995, 38, 4191.
- Hartmann, R. W.; Waächter, G. A.; Sergejew, T.; Würtz, R.; Düerkop, J. Arch. Pharm. Pharm. Med. Chem. 1995, 328, 573.
- Wächter, G. A.; Hartmann, R. W.; Sergejew, T.; Grün, G. L.; Ledergerber, D. J. Med. Chem. 1996, 39, 834.
- Hartmann, R. W.; Frotscher, M.; Ledergerber, D.; Wächter, G. A.; Grün, G. L.; Sergejew, T. F. Arch. Pharm. Pharm. Med. Chem. 1996, 329, 251.
- Al-Hamrouni, A. M.; Ahmadi, M.; Nicholls, P. J.; Smith, J. H.; Lombardi, P.; Pestellini, V. Pharm. Sci. 1997, 3, 259.
- Ideyama, Y.; Kudoh, M.; Tanimoto, K.; Susaki, Y.; Nanya, T.; Nakahara, T.; Ishikawa, H.; Yoden, T.; Okada, M.; Fujikura, T.; Akaza, H.; Shikama, H. Prostate 1998, 37, 10.
- 28. Zhuang, Y.; Hartmann, R. W. Arch. Pharm. Pharm. Med. Chem. 1998, 331, 36.
- 29. Zhuang, Y.; Hartmann, R. W. Arch. Pharm. Pharm. Med. Chem. 1999, 332, 25.
- Wachall, B. W.; Hector, M.; Zhuang, Y.; Hartmann, R. W. Bioorg. Med. Chem. 1999, 7, 1913.
- 31. Zhuang, Y.; Wachall, B. W.; Hartmann, R. W. Bioorg. Med. Chem. 2000, 8, 245.
- Hartmann, R. W.; Hector, M.; Haidar, S.; Ehmer, P.; Reichert, W.; Jose, J. Med. Chem. 2000, 43, 4266.
- Hartmann, R. W.; Hector, M.; Wachall, B. G.; Paluszcak, A.; Palzer, M.; Huch, V.; Veith, M. J. Med. Chem. 2000, 43, 4437.
- 34. Haidar, S.; Hartmann, R. W. Arch. Pharm. 2002, 335, 526.
- Hartmann, R. W.; Ehmer, P. B.; Haidar, S.; Hector, M.; Jose, J.; Klein, C. D. P.; Seidel, S. B.; Sergejew, T.; Wachall, B. G.; Wächter, G. A.; Zhuang, Y. Arch. Pharm. 2002, 335, 119.
- Haidar, S.; Ehmer, P. B.; Barassin, S.; Batzl-Hartmann, C.; Hartmann, R. W. J. Steroid Biochem. Mol. Biol. 2003, 84, 555.
- Clement, O. O.; Freeman, C. M.; Hartmann, R. W.; Paluszcak, A.; Handratta, V. D.; Vasaitis, T. S.; Brodie, A. M. H.; Njar, V. C. O. J. Med. Chem. 2003, 46, 2345.
- Pinto-Bazurco Mendieta, M. A. E.; Negri, M.; Jagusch, C.; Hille, U. E.; Müller-Vieira, U.; Schmidt, D.; Hansen, K.; Hartmann, R. W. *Bioorg. Med. Chem. Lett.* 2008, 18, 267.
- Pinto-Bazurco Mendieta, M. A. E.; Negri, M.; Jagusch, C.; Müller-Vieira, U.; Lauterbach, T.; Hartmann, R. W. J. Med. Chem. 2008, 51(16), 5009.
- 40. Zhuang, Y.; Wachall, B. G.; Hartmann, R. W. Bioorg. Med. Chem. 2000, 8, 1245.

- 41. Leroux, F.; Hutschenreuter, T.; Charrière, C.; Scopelliti, R.; Hartmann, R. W. Helv. Chim. Acta **2003**, 86, 2671.
- 42. Hutschenreuter, T. U.; Ehmer, P. B.; Hartmann, R. W. J. Enzyme Inhib. Med. Chem. 2004, 18, 17.
- Jagusch, C.; Negri, M.; Hille, U. E.; Hu, Q.; Bartels, M.; Jahn-Hoffmann, K.; Pinto-Bazurco Mendieta, M. A. E.; Rodenwaldt, B.; Müller-Vieira, U.; Schmidt, D.; Lauterbach, T.; Recanatini, M.; Cavalli, A.; Hartmann, R. W. *Bioorg. Med. Chem.* 2008, 16, 1992.
- 44. Hu, Q.; Negri, M.; Jahn-Hoffmann, K.; Zhuang, Y.; Olgen, S.; Bartels, M.; Müller-Vieira, U.; Lauterbach, T.; Hartmann, R. W. *Bioorg. Med. Chem.* 2008, 16, 7715.
- Matsunaga, N.; Kaku, T.; Ojida, A.; Tanaka, T.; Hara, T.; Miki, H.; Iwasaki, M.; Yamaoka, M.; Kusaka, M.; Tasaka, A. Bioorg. Med. Chem. 2004, 12, 4313.
- 46. Blatter, K.; Schlueter, A.-D. Synthesis 1989, 5, 356.
- 47. Méric, R.; Vigneron, J.-P. Bull. Soc. Chim. France 1973, 327.
- 48. Still, W. C.; McDonald, J. H., III Tetrahedron Lett. 1980, 21, 1031.
- 49. Brown, J. D. Tetrahedron: Asymmetry 1992, 3, 1551.
- Ojida, A.; Matsunaga, N.; Kaku, T.; Tasaka, A. Tetrahedron: Asymmetry 2004, 15, 1555.
- 51. Matsunaga, N.; Kaku, T.; Ojida, A.; Tasaka, A. *Tetrahedron: Asymmetry* **2004**, *15*, 2021.

- 52. Tasaka, A.; Tamura, N.; Matsushita, Y.; Teranishi, K.; Hayashi, R.; Okonogi, K.; Itoh, K. Chem. Pharm. Bull. **1993**, 41, 1035.
- 53. Wilkinson, G. R. N. Eng. J. Med. 2005, 352, 2211.
- 54. Caraco, Y. N. Eng. J. Med. 2004, 351, 2867.
- 55. Gao, Y.; Liu, D.; Wang, H.; Zhu, J.; Chen, C. Xenobiotica 2010, 40, 467.
- 56. Projean, D.; Morin, P.-E.; Tu, T. M.; Ducharme, J. Xenobiotica 2003, 33, 841.
- 57. Vuligonda, V.; Chandraratna, R. A. S. Bioorg. Med. Chem. Lett. 1999, 9, 2289.
- 58. Li, J.-S.; Li, Y.; Son, C.; Brodie, A. M. H. Prostate 1998, 36, 92.
- 59. Uzgiris, V. I.; Graves, P. E.; Salhanick, H. A. Biochemistry 1977, 16, 593.
- 60. Greenlee, W. F.; Poland, A. J. Pharmacol. Exp. Ther. 1978, 205, 596.
- Goldstein, J. A.; Faletto, M. B.; Romkes-Sparks, M.; Sullivan, T.; Kitareewan, S.; Raucy, J. L. Biochemistry 1994, 33, 1743.
- Reiners, J. J., Jr.; Cantu, A. R.; Pavone, A.; Smith, S. C.; Gardner, C. R.; Laskin, D. L. Anal. Biochem. 1990, 188, 317.
- Miners, J. O.; Smith, K. J.; Robson, R. A.; McManus, M. E.; Veronese, M. E.; Birkett, D. J. Biochem. Pharmacol. 1988, 37, 1137.
- Chiba, K.; Manabe, K.; Kobayashi, K.; Takayama, Y.; Tani, M.; Ishizaki, T. Eur. J. Clin. Pharmacol. 1993, 44, 559.
- 65. Kronbach, T.; Mathys, D.; Gut, J.; Catin, T.; Meyer, U. A. Anal. Biochem. 1987, 162, 24.
- 66. Reinke, L. A.; Moyer, M. J. Drug Metab. Dispos. 1985, 13, 548.